Formulaire 10-K / A Canbiola, Inc. Pour: 31 décembre

Des nouvelles et des recherches avant d’en entendre parler sur CNBC et d’autres. Réclamez votre essai gratuit de 2 semaines à StreetInsider Premium ici.

UNI
ÉTATS

TITRES
ET COMMISSION D'ÉCHANGE

Washington,
D.C. 20549

FORME
10-K / A

(Marque
Un)

(X)
RAPPORT ANNUEL CONFORMÉMENT À L'ARTICLE 13 OU 15 D) DE LA LOI SUR L'ÉCHANGE DE TITRES DE 1934

Pour
l'exercice clos le 31 décembre 2018

OU

()
RAPPORT DE TRANSITION EN VERTU DE LA SECTION 13 OU 15 D) DE L’ÉCHANGE DE VALEURS MOBILIÈRES

Pour
la période de transition du ____________ au ____________

Commission
Numéro de dossier: 333-208293

CANBIOLA,
INC.

(Exact
nom du titulaire tel que spécifié dans sa charte)

Floride
    
    20-3624118

(Etat
                                         ou autre juridiction de

incorporation
        ou organisation)

(I.R.S.
                                         Employeur

Identification
        Nombre)

960
South Broadway, Suite 120, Hicksville NY 11801,

(Adresse
des principaux bureaux exécutifs)

516-595-9544

Titulaire
numéro de téléphone, y compris l'indicatif régional:

Aucun

Titres
Enregistré conformément à l'alinéa 12b) de la loi:

Commun
Stock, valeur nominale 0,001 $ par action

Titres
Enregistré conformément à l'alinéa 12g) de la loi:

Indiquer
par coche si la personne inscrite est un émetteur chevronné bien connu, au sens de la règle 405 de la loi intitulée Securities Act. Oui ( )
Non (X)

Indiquer
par coche si l’inscrit n’est pas tenu de déposer des rapports en vertu de l’article 13 ou de l’alinéa 15d) de la Loi. Oui ( )
Non (X)

Indiquer
par marque de contrôle si l'inscrit (1) a déposé tous les rapports qui doivent être produits en vertu de l'article 13 ou de l'alinéa 15 (d) de la Securities Exchange
Acte de 1934 au cours des 12 derniers mois (ou pendant une période plus courte obligeant le titulaire à déposer de tels rapports),
et (2) a été soumis à de telles exigences de dépôt au cours des 90 derniers jours. Oui (X) Non ()

Indiquer
cocher si le déclarant a soumis électroniquement et affiché sur son site Web corporatif, le cas échéant, tous les
Le fichier de données doit être soumis et affiché conformément à la règle 405 du règlement S-T (§ 232.405 du présent chapitre) au
12 mois précédents (ou pendant un délai aussi court que le déclarant était tenu de soumettre et de poster de tels fichiers). Oui (X) Non ()

Indiquer
par coche si la divulgation des déclarants délinquants conformément à la rubrique 405 du règlement S-K ne figure pas dans les présentes et ne
à la connaissance du déposant, dans des procurations définitives ou des déclarations de renseignements incorporées par référence
dans la partie III de la présente formule 10-K ou de toute modification de cette formule 10-K. ()

Indiquer
par coche si le déclarant est un grand déposant accéléré, un déposant accéléré, un déposant non accéléré, une déclaration plus petite
entreprise ou une entreprise en croissance émergente. Voir les définitions de «grand déposant accéléré», «déposant accéléré»,
«Société déclarante plus petite» et «société à croissance émergente» dans la règle 12b-2 de la loi intitulée Exchange Act. (Cochez une):

Grand
    Filer accéléré
    ()
    Accéléré
    classeur
    ()
    

    Non accéléré
    classeur
    ()
    (Ne pas vérifier si une société déclarante plus petite)
    Plus petite
    société déclarante
    (X)

    Émergent
    Société de croissance (X)

Si
société en croissance émergente, indiquez par coche si le déclarant a choisi de ne pas utiliser la période de transition prolongée pour
se conformer aux normes de comptabilité financière nouvelles ou révisées fournies en vertu de l’alinéa a) du paragraphe 13 de la loi intitulée Exchange Act. ()

Indiquer
cocher si le déclarant est une société écran (au sens de la règle 12b-2 de la Loi). Oui () Non (X)

le
La valeur marchande globale des actions avec droit de vote détenues par les personnes non affiliées de la personne inscrite au 30 juin 2018 s'élevait à 4 466 469 $, sur la base des
dernier prix de vente déclaré des actions ordinaires de la personne inscrite sur les marchés de gré à gré à cette date.

Comme
du 12 avril 2019, la personne inscrite avait en circulation 548 487 714 actions ordinaires d'une valeur nominale de 0,00 $ par action.

NOTE EXPLICATIVE

Canbiola, Inc. (la «société»)
a par inadvertance fourni un numéro de téléphone incorrect dans son rapport annuel sur formulaire 10-K pour l'exercice clos le décembre
31, 2018 (le «dépôt initial») et n’incluait pas les données interactives (également appelées XBRL) pour le dépôt initial.
La présente modification n ° 1 sur le formulaire 10-K (la «modification n ° 1») est déposée uniquement pour inclure le contenu interactif de la société.
données et de modifier le numéro de téléphone de la société.

CANBIOLA,
INC.

2017
FORMULAIRE 10-K RAPPORT ANNUEL

TABLE
DES MATIERES

DE PRÉCAUTION
NOTE CONCERNANT LES DÉCLARATIONS PROSPECTIVES

Certain
Les déclarations contenues ou incorporées par référence dans le présent rapport annuel sur formulaire 10-K sont considérées comme des déclarations prospectives.
(au sens de la loi Private Securities Litigation Reform Act de 1995) concernant nos activités, nos résultats d'exploitation, la
performance et / ou la situation financière, en fonction des attentes, plans, estimations, hypothèses et projections actuels de la direction.
Des déclarations prospectives sont incluses, par exemple, dans les discussions sur:

●
    stratégie;

    
    ●
    Nouveau
    découverte et développement de produits;

    
    ●
    actuel
    ou en attente d'essais cliniques;

    
    ●
    notre
    la capacité des produits à démontrer leur efficacité ou un profil d’innocuité acceptable;

    
    ●
    actes
    par les autorités de régulation;

    
    ●
    produit
    la fabrication, y compris nos arrangements avec des fournisseurs tiers;

    
    ●
    produit
    introduction et vente;

    
    ●
    redevance
    et revenus de contrat;

    
    ●
    les frais
    et revenu net;

    
    ●
    crédit
    et gestion du risque de change;

    
    ●
    liquidité;

    
    ●
    atout
    et la gestion des risques de responsabilité;

    
    ●
    la
    l'issue des litiges et autres procédures;

    
    ●
    intellectuel
    droits de propriété et protection;

    
    ●
    économique
    les facteurs;

    
    ●
    concurrence;
    et

    
    ●
    légal
    des risques.

Tout
Les déclarations contenues dans le présent rapport qui ne sont pas des déclarations de faits historiques peuvent être considérées comme des déclarations prospectives. Tourné vers l'avenir
les déclarations sont généralement identifiées par les mots «s'attend à», «anticipe», «croit», «a l'intention»,
«Estimations», «objectifs», «plans», «peut», «pourrait», «sera»
«Continuera», «cherchera», «devrait», «prévoir», «potentiel», «perspectives»
«Orientation», «cible», «prévision», «probable», «possible» ou négatif
de tels termes et expressions similaires. Les énoncés prospectifs sont sujets à changement et peuvent être affectés par des risques et des incertitudes.
dont la plupart sont difficiles à prévoir et sont généralement hors de notre contrôle. Les déclarations prospectives ne sont valables qu’à la date
elles sont faites et nous n’assumons aucune obligation de mettre à jour les déclarations prospectives à la lumière de nouvelles informations ou d’événements futurs,
sauf si la loi l’impose, même si nous avons l’intention de continuer à respecter nos obligations en matière d’information continue aux termes de la législation américaine.
lois et autres lois applicables.

nous
vous avertir qu'un certain nombre de facteurs importants pourraient entraîner des résultats substantiels différents de ceux exprimés
impliquées dans les déclarations prospectives, et par conséquent, vous ne devez pas trop vous fier à celles-ci. Ces facteurs
incluent, entre autres, ceux décrits aux présentes sous la rubrique «Facteurs de risque» et ailleurs dans le présent rapport annuel et dans notre
autres rapports publics déposés auprès de la Securities and Exchange Commission. Il n'est pas possible de prédire ou d'identifier tous ces facteurs,
par conséquent, les facteurs mentionnés ne constituent pas une analyse complète de tous les risques ou incertitudes potentiels
cela peut affecter les déclarations prospectives. Si ces risques ou incertitudes ou d’autres se matérialisent, ou si les hypothèses sous-jacentes
l’une des déclarations prospectives s’avère inexacte, notre performance réelle et nos actions futures pourraient être sensiblement différentes de
celles qui sont exprimées ou impliquées dans ces déclarations prospectives. Nous ne pouvons garantir que nos estimations ou nos attentes
s'avéreront exacts ou que nous pourrons atteindre nos objectifs stratégiques et opérationnels.

Tourné vers l'avenir
Ces déclarations sont basées sur les informations dont nous disposons lorsque ces déclarations sont faites ou sur la conviction de bonne foi de la direction à cet égard.
temps en ce qui a trait aux événements futurs et sont assujettis à des risques et à des incertitudes importants qui pourraient nuire au rendement réel
ou les résultats diffèrent sensiblement de ceux exprimés ou suggérés par les déclarations prospectives.

En outre,
de nouveaux risques apparaissent régulièrement et il est impossible pour notre direction de prévoir ou d’énoncer tous les risques auxquels nous sommes confrontés, et nous ne pouvons pas non plus évaluer ces risques.
l’impact de tous les risques sur nos activités ou la mesure dans laquelle tout risque, ou combinaison de risques, peut entraîner des résultats réels
diffèrent de ceux contenus dans les déclarations prospectives. Tous les énoncés prospectifs inclus dans le présent prospectus sont
sur la base des informations dont nous disposons à la date du présent rapport annuel. Sauf dans la mesure requise par les lois ou règles applicables,
nous n'assumons aucune obligation de mettre à jour ou de réviser publiquement tout énoncé prospectif, que ce soit à la suite de nouvelles informations,
événements futurs ou autres. Tous les énoncés prospectifs ultérieurs, écrits et verbaux, attribuables à nous ou à des personnes agissant
notre nom est expressément qualifié dans son intégralité par les mises en garde contenues ci-dessus et tout au long du présent rapport annuel.

DÉBUT DE SAUT
NOTRE LOI SUR LES STARTUPS D'AFFAIRES

nous
en tant que «société à croissance émergente» au sens de la section 101 de la loi intitulée Jumpstart our Business Startups Act («JOBS
Loi ») car nous n’avions pas plus de 1 000 000 000 $ de revenu brut annuel et n’avions pas ce montant au 31 décembre
2018, dernier jour de notre dernier exercice financier. Nous choisissons d’utiliser la période de transition prolongée pour nous conformer aux nouvelles règles ou aux normes révisées.
normes comptables en vertu de l’article 102 (b) (1) de la loi sur l’emploi.

Comme
société en croissance émergente, nous sommes autorisés et avons l’intention de nous prévaloir d’exemptions à certaines obligations de divulgation qui
par ailleurs applicable aux sociétés publiques. Ces dispositions comprennent, sans toutefois s'y limiter:

●
    étant
    autorisés à ne présenter que deux ans d’états financiers vérifiés et deux ans seulement de «rapports de gestion» connexes.
    Discussion et analyse de la situation financière et des résultats d’exploitation »dans le présent rapport annuel;

    
    ●
    ne pas
    étant tenu de se conformer aux exigences d'attestation de l'auditeur de la section 404 de la loi Sarbanes-Oxley de 2002, telle que modifiée
    («Loi Sarbanes-Oxley»);

    
    ●
    réduit
    obligations de divulgation concernant la rémunération des dirigeants dans nos rapports périodiques, nos relevés de procuration et nos relevés d’enregistrement;
    et

    
    ●
    exemptions
    de la tenue d’un vote consultatif non contraignant sur la rémunération des dirigeants et de l’approbation par les actionnaires de toute
    paiements en parachute non approuvés précédemment.

nous
restera une société en croissance émergente jusqu’à ce que nous ayons au plus tôt pris naissance: (i) nos revenus bruts annuels d’un milliard de dollars ou plus;
(ii) la fin de l'exercice 2019; (iii) notre émission, sur une période de trois ans, d'une dette non convertible de plus d'un milliard de dollars;
et (iv) la fin de l’exercice au cours duquel la valeur marchande de nos actions ordinaires détenues par des sociétés non affiliées dépassait 700 millions de dollars.
le dernier jour ouvrable de notre deuxième trimestre fiscal.

PARTIE
je

Entreprise
Vue d'ensemble

Canbiola,
Inc. a été incorporée à l’origine sous le nom de WrapMail, Inc. («WRAP») en Floride le 11 octobre 2005 afin d’exploiter une
segment de l’industrie de la publicité Web basé pour l’essentiel sur les services. À compter du 27 décembre 2010, le WRAP a effectué un transfert de 10 pour 1
stock fractionné de ses actions ordinaires. À compter du 4 juin 2013, WRAP a procédé à un fractionnement d'actions 1 pour 10 de ses actions ordinaires. le
Les états financiers consolidés ci-joints tiennent compte de manière rétroactive de ces divisions d’actions.

Efficace
Le 5 janvier 2015, WRAP a acquis la propriété exclusive de Prosperity Systems, Inc. («Prosperity»), une société new-yorkaise constituée en société.
2 avril 2008, afin d’acquérir la suite logicielle de productivité bureautique de Prosperity en complément du logiciel WRAP existant.
propriété intellectuelle. Après son acquisition, la société a transféré les activités de Prosperity à WRAP et est actuellement en
le processus de dissolution de la prospérité. Pour les périodes présentées, les actifs, les passifs, les produits et les charges sont ceux de
l'entreprise. La prospérité n'a eu aucune activité pour les périodes présentées.

Autour
Au cours du premier trimestre de 2017, la société a commencé sa transition vers le secteur du CBD du chanvre et offre maintenant principalement des services de santé et de beauté.
produits et suppléments contenant de la CBD. Le 15 mai 2017, WRAP a pris le nom de Canbiola, Inc. (la «société» ou
“CANB” ou “Canbiola”) pour refléter sa transition.

Affaires

le
L’activité principale de la société est le développement, la production et la vente de produits et de dispositifs de livraison contenant du CBD. le
Les produits de la société contiennent du CBD dérivé du chanvre et comprennent des produits tels que des huiles, des crèmes, des hydratants, des isolats et des gels.
casquettes. En plus d’offrir des produits à étiquette blanche, Canbiola a développé sa propre gamme de produits exclusifs, ainsi que
recherche de valeur synergique par l’acquisition de produits et de marques dans l’industrie du chanvre. Canbiola veut être le premier fournisseur
produits de CBD au chanvre naturel de la plus haute qualité sur le marché, en achetant la meilleure matière première et en développant une
Nous pensons que des produits améliorera la vie des gens dans divers domaines.

"CBD"
Affaires

Cannabidiol
(«CBD») est l’un des 85 composés naturels (cannabinoïdes) présents dans le chanvre industriel (il est également contenu
marijuana, mais les produits de la société ne sont dérivés que du chanvre). Le CBD est non psychoactif et on pense qu'il a de nombreux
utilisations, y compris, mais sans s'y limiter, la douleur, l'insomnie, l'épilepsie, l'anxiété, l'inflammation et les nausées. Contrairement à la CDB dérivée de
marijuana, le CBD dérivé des graines et des tiges de chanvre industriel est généralement considéré comme «légal» aux États-Unis, de sorte que
tant qu’il contient moins de 0,3% de «THC», un autre cannabinoïde psychoactif, présent dans le cannabis. Ce prétendu
«Statut juridique» parce que le Farm Bill de 2018 a supprimé le chanvre en tant que drogue de l'annexe I en vertu de la Loi sur les substances contrôlées
et le chanvre peut maintenant être cultivé comme culture de base, avec des restrictions; cependant, le Farm Bill de 2018 ne légalisait pas spécifiquement la CDB.
Jusqu'à ce que le Congrès promulgue les règles et règlements relatifs à la CDB dérivée du chanvre en vertu de la loi agricole de 2018, le
Le statut de la CDB provenant du chanvre, ou les processus que la Société pourrait avoir à mettre en œuvre (et à quels frais), sont encore inconnus. Un similaire
Ce paradigme existe en vertu de diverses lois nationales auxquelles la société devra se conformer. Dans tous les cas, la CDB dérive de la marijuana,
La marijuana et les autres dérivés de la marijuana sont illégaux aux États-Unis en vertu de la Loi sur les substances contrôlées.
légalement sur le plan médical ou récréatif dans de nombreux États. C’est pourquoi la société a mis en place des procédures lui permettant de
dérive du chanvre conformément à la loi agricole. La société fait tester toutes ses matières premières (isolat) à base de chanvre par
un laboratoire indépendant à trois parties et ces résultats sont publiés sur le site Web de la société.

Dans
Afin de faciliter ses opérations, la Société a (et va) créer ou acquérir un certain nombre de filiales. Son objectif est de finalement
exploiter un conglomérat de chanvre à intégration verticale dont les activités vont de la graine à la vente. Actuellement, la société
L’objectif principal est le développement, la vente et la fabrication de produits à base de CBD. Les produits de la société sont commercialisés sous le nom commercial
«Canbiola.», Et vendu via son site Web et par l'intermédiaire de médecins et d'autres professionnels de la santé avec lesquels la Société entre
dans les accords de distribution. La société fabrique et / ou vend également des produits CBD de marque distincte par l’intermédiaire de ses filiales.
et des sites Web pour les marques «Pure Leaf Oil» et «Seven Chakras».

Dans
En décembre 2018, la société a acquis 100% de la participation de membre dans Pure Health Products, LLC, une société à responsabilité limitée de New York.
société («PHP» ou «Pure Health Products»), avec laquelle elle avait et a un accord de production exclusif,
aux termes d’une convention d’acquisition (la «convention d’acquisition de PHP»). PHP fabrique et emballe les produits de la société
Produits infusés de CBD. PHP peut également apposer une marque blanche, changer l’image de marque ou renommer les produits de la société conformément à la directive «marque blanche».
accords »conclus entre la société et / ou PHP et des clients tiers. Grâce à PHP, la société est en mesure de contrôler
processus de fabrication de ses produits tout en réduisant ses coûts de production. En janvier 2019, PHP a acquis certains actifs de
Seven Chakras, LLC («Seven Chakras»), un ancien concurrent, dont les actifs comprenaient les droits et le titre de (i) Seven
Formules, méthodes, secrets commerciaux et savoir-faire exclusifs des chakras liés à la production de la CDB de Seven Chakras
(ii) le nom commercial, le nom de domaine et les sites de médias sociaux de Seven Chakras, et (iii) les autres actifs de Seven Chakras, y compris
mais ne se limite pas aux matières premières, aux équipements, au matériel d’emballage et d’étiquetage, aux listes de diffusion et au matériel de marketing. L'entreprise
estime que l’acquisition des actifs de Seven Chakra apportera une valeur relutive et étendra la base de marché de la société.
Les clients de Severn Chakras ont une clientèle fidèle dans le nord-ouest et complimentent les marques Canbiola et Pure Leaf Oil avec des
de nouveaux produits tels que les bombes de bain, les produits anti-stress et les lotions. Seven Chakras a son propre site internet et continue
dans son marketing direct à sa clientèle.

Dans
Novembre 2018, la Société a créé Duramed, Inc., société du Nevada («Duramed») pour faciliter la fabrication et la
vente de matériel médical durable incorporant la CDB. Le 14 janvier 2019, Duramed a conclu un protocole d’entente (le
«Sam MOU») avec Sam International («Sam») et ZetrOZ Systems LLC («ZetrOZ» et collectivement
avec Sam, les «Fabricants»). Conformément au mémorandum d’accord de Sam, les fabricants ont concédé à Duramed le droit exclusif de
distribuez les correctifs sam® Pro 2.0 (SA271) et sam® Gel Coupling (UB-14-72) aux États-Unis pour les dommages corporels
Protection / Marché sans faille pendant la durée du PE. Duramed a accepté d'acheter des minimums mensuels auprès des fabricants
à un prix par part de 2 447 $. L’exclusivité de la licence de distribution attribuée à Duramed en vertu du protocole d’entente dépend du
respecter le minimum mensuel. En outre, Duramed a obtenu le droit de distribuer des correctifs sam® Gel Capture (UB-14-24).
Duramed obtiendra des rabais de 2% à 3% en fonction du volume de produits vendus par elle. La durée initiale du PE Sam expire en décembre.
31 2019 (le «terme initial»). L’accord envisagé par le protocole d’entente sera automatiquement renouvelé pour un an supplémentaire.
terme à la fin de chaque année civile, à condition que les minimums mensuels soient atteints. L'axe principal du Duramed
Division doit commercialiser auprès des patients via des médecins via un programme de location d’appareils remboursable par les assureurs
réduction de la douleur et guérison plus rapide.

le
Les marchés de la CDB et du cannabis sont inondés de concurrence allant des entreprises familiales aux conglomérats de plusieurs millions de dollars.
beaucoup ont des antécédents d’exploitation plus longs, plus de capital et / ou plus de connaissances du secteur que la société. La société espère s'associer
avec ou engager des spécialistes de l’industrie pour aider à la différencier de ses nombreux concurrents. Un de ces points de différenciation
est son «certificat d’analyse» indépendant réalisé par une tierce partie sur tous les produits d’isolats CBD
il achète et affiche ces résultats de laboratoire sur son site Web.

le
La Food and Drug Administration (FDA) n’a pas évalué les déclarations trouvées dans le présent document et les produits de la société sont
pas destiné à diagnostiquer, traiter, guérir ou prévenir toute maladie ou condition médicale.

WRAPmail

le
La société possède une technologie brevetée qui combine un contenu marketing personnalisé avec le courrier électronique de l'organisation pour fournir une nouvelle génération.
plate-forme de marketing pour les organisations et à usage personnel. WRAPMail avait fourni des solutions logicielles pour le marketing et n’est plus
être vendu ou entretenu.

nous
ne sommes au courant d'aucun concurrent développant une solution similaire à WRAPmail, ce qui pourrait nous donner un avantage concurrentiel. Toutefois,
nous pouvons être confrontés à la concurrence de papier à en-tête stationnaire, de courrier en vrac et de fournisseurs de produits similaires.

Actuellement
la société ne recherche pas de clients supplémentaires pour WRAPmail mais continue de servir les clients actuels utilisant le logiciel.

Bullseye

le
Bullseye Productivity Suite est un système basé sur le cloud qui regroupe tous les outils de productivité de bureau nécessaires en un seul outil en ligne.
une expérience accessible partout où vous en avez besoin avec des mécanismes complets de récupération après sinistre. Toutes les fonctions et caractéristiques
sont audités pour aider les utilisateurs avec les problèmes de gouvernance d'entreprise et de conformité.

le
La société ne recherche pas actuellement de nouveaux clients pour Bullseye, mais continue de desservir la base de clients existante.

Intellectuel
Propriété

nous
posséder les brevets suivants pour notre technologie WRAPmail: brevet américain no. 8572275 délivré le 29 octobre 2013. Ce brevet expire dans
Octobre 2033. Le 20 juillet 2015, WRAPmail a déposé un nouveau brevet sous le titre: Méthode, système et logiciel d'extraction dynamique.
Contenu pour intégration avec les messages instantanés, quelle application est encore en attente et non poursuivie activement par la société.

le
Les brevets ci-dessus concernent les divisions de la gestion de documents et du marketing par courrier électronique. En raison de la diminution des revenus de ces divisions,
Le comptable de la société a décidé de ramener la juste valeur de ces brevets à 0 $.

le
La société emploie, par l’intermédiaire de sa division Pure Health Products LLC, deux chercheurs à temps plein sur les produits et des experts en technologie CBD qui,
Définir quotidiennement les normes de qualité, le statut de développement des nouveaux produits et les agendas du calendrier sous la supervision directe
l’équipe de direction de la société.

Employés

le
La société compte actuellement quatre employés à plein temps et sept sous contrats de services.

Rapports
aux détenteurs de sécurité

Notre
Les actions ordinaires sont enregistrées en vertu de la loi Securities Exchange Act de 1934 et nous sommes tenus de déposer les rapports courants, trimestriels et annuels.
rapports et autres informations avec la SEC. Vous pouvez lire et copier tout document que nous avons déposé lors de la consultation publique de la SEC.
100 F. Street, N.E., Washington, DC 20549. Veuillez appeler la SEC au 1-800-732-0330 pour plus d'informations sur ses
installations de référence publiques. Nos dépôts auprès de la SEC sont mis à votre disposition gratuitement sur le site Web de la SEC à l’adresse www.sec.gov. nous
sont un déposant électronique auprès de la SEC et, à ce titre, nos informations sont disponibles sur le site Internet de la SEC
qui contient des rapports, des procurations et des déclarations d’information et d’autres informations concernant les émetteurs qui déposent leurs
la seconde. Ces informations sont disponibles sur www.sec.gov et sur notre site Web www.canbiola.com.

Recherche
et développement

Dans
Au cours des exercices 2017 et 2018, nous avons dépensé respectivement 37 000 $ et 75 000 $ en recherche et développement, qui correspond aux dépenses engagées.

Gouvernement
Règlement

le
La culture et la vente de chanvre et de produits à base de chanvre sont régies par le gouvernement fédéral en vertu du Farm Bill des États-Unis. La facture agricole de 2018 supprimée
le chanvre en tant que substance de l'annexe 1 en vertu de la Loi sur les substances contrôlées; Cependant, les règles et règlements relatifs à la fabrication et à
La vente de produits à base de DBC en vertu de la loi agricole doit encore être promulguée et devrait avoir une incidence sur les activités de la société.
À mesure que le secteur juridique de la DBC et nos gammes de produits se développent, il est incertain que d’autres régimes et agences statutaires commenceront à
réglementer nos produits CBD. La FDA considère toujours que l'ajout de CBD à des produits alimentaires ou à des suppléments est illégal.
et interdit la publicité des produits à base de CBD avec des allégations de santé. La société doit également se conformer aux lois de chaque État
concernant la vente de produits à base de CBD à base de chanvre. Ces réglementations peuvent affecter, entre autres, la manière dont la société fabrique
et distribue ses produits, la façon dont la société est taxée, la manière dont la société banque, la localisation des installations de la société,
contenu et les tests des produits de la société, ainsi que la qualité des services de la société.

À travers
nos plates-formes de gestion de documents et de marketing par e-mail, nous sommes également soumis aux lois et règlements généraux
Réglementations et lois fédérales et nationales régissant spécifiquement Internet et le commerce électronique. Lois et règlements existants et futurs
peut entraver la croissance d’Internet, du commerce électronique ou d’autres services en ligne et augmenter le coût de la fourniture de services en ligne.
Ces réglementations et lois peuvent couvrir les concours, les taxes, les tarifs, la vie privée des utilisateurs, la protection des données, la tarification, le contenu, les droits d’auteur,
distribution électronique, contrats électroniques et autres communications, protection des consommateurs, accès Internet haut débit résidentiel et
caractéristiques et qualité des services. Il n’est pas clair comment les lois existantes régissant des questions telles que la propriété, les ventes,
L’utilisation et d’autres taxes, la diffamation et la confidentialité des données personnelles s’appliquent à Internet et au commerce électronique. Une résolution défavorable de ces problèmes peut
nuire à nos activités et à nos résultats d’exploitation.

Transfert
Agent

nous
avait engagé Island Stock Transfer, situé au 15500 Roosevelt Blvd, Suite 301, Clearwater, FL 33760, en tant que notre agent de transfert d’actions.
Téléphone: 727.289.0010. Notre ancien directeur, Carl Dilley, est l'un des principaux d'Island Stock Transfer.

Sur
Le 1er avril 2019, nous avons remplacé les agents de transfert par Transhare Corporation, situé au 15500 Roosevelt Blvd, Suite 302, Clearwater.
FL 33760.

nous
sont une société déclarante plus petite et non tenue de fournir les informations contenues dans ce poste.

Point 1B.
    Commentaires du personnel non résolus

ne pas
en vigueur.

le
La société ne possède actuellement aucun bien immobilier. Nous louons cependant des bureaux à Hicksville, dans l’État de New York. De l'entreprise
Pure Health Products, une filiale à part entière, exploite son usine de fabrication dans l’État de Washington.

Point 3
    Poursuite judiciaire

nous
ne sommes au courant d'aucune procédure judiciaire en cours ou imminente dans laquelle nous sommes impliqués, à l'exception de ce qui est divulgué aux présentes. Sur ou autour de
11 mai 2018, la Société a engagé une procédure d’arbitrage contre T8 Partners, Inc., une société new-yorkaise («T8»),
conformément aux règles de l’American Arbitration Association («AAA»), pour rupture de contrat et restitution de 2,5 millions d’actions de
actions ordinaires de la Société pour non-exécution par T8 dans le cadre d’un contrat de services. L'affaire n ° 01-18-0001-8823 est en cours d'examen.
entendu au bureau régional AAA de Los Angeles.

Point 4
    Informations sur la sécurité des mines

ne pas
en vigueur.

PARTIE
II

Point 5
    Marché pour les inscrits
    Actions ordinaires, questions d'actionnaires connexes et achats d'émetteurs de titres de participation par l'émetteur

Marché
Information

Nos actions ordinaires sont cotées sur OTCQB Market sous le symbole «CANB». Notre
les actions ordinaires ont commencé à être négociées en avril 2011.
dans nos actions ordinaires a historiquement manqué de volume constant, et le prix du marché a été volatil.

le
Le tableau ci-dessous présente, pour les périodes indiquées, les prix les plus élevés et les plus bas des actions ordinaires de la société.
selon les informations fournies par OTC Market. Les prix indiqués ci-dessous correspondent aux prix entre détaillants, sans la majoration, la réduction, la
ou de commission, et peuvent ne pas nécessairement représenter des transactions réelles.

2018

    
    Haute
    Faible

    Premier quart
    0,05 USD
    0,02 $

    Deuxième quartier
    0,03 USD
    0,01 USD

    Troisième quart
    0,10 USD
    0,01 USD

    Quatrième trimestre
    0,10 USD
    0,03 USD

2017

    
    Haute
    Faible

    Premier quart
    0,09 $
    0,07 USD

    Deuxième quartier
    0,04 USD
    0,03 USD

    Troisième quart
    0,03 USD
    0,03 USD

    Quatrième trimestre
    0,04 USD
    0,03 USD

le
Le dernier prix de vente déclaré des actions ordinaires de la Société au 12 avril 2019 était de 0,039 USD par action.

Record
Les porteurs

Comme
Le 12 avril 2019, il y avait 548 487 714 actions ordinaires émises et en circulation à environ 163 actionnaires inscrits.

Les dividendes

le
La société a versé des dividendes en nature de 13 779 $ sur ses actions privilégiées de catégorie B par l'émission d'actions ordinaires aux détenteurs de la catégorie B.
en 2018 et 0 $ en 2017. Chaque action des actions privilégiées de série B a la priorité sur les dividendes, les distributions et les paiements.
lors de la liquidation, de la dissolution et de la liquidation de la Société et donne droit à un dividende cumulatif mais non composé
au taux de 5% l'an, qu'ils soient déclarés ou non. Au bout de six mois à compter de la date d’émission, cette action et toute somme courue mais non payée
les dividendes peuvent être convertis en actions ordinaires au prix de conversion qui est le plus bas de (i) 0,0101 USD; ou (ii) le plus bas des
Prix ​​moyen pondéré en dollars des actions ordinaires de CANB le jour de bourse précédant le jour de la conversion ou du volume en dollars
prix moyen pondéré des actions ordinaires de CANB le jour de la conversion. Les actions privilégiées série B n’ont pas de droit de vote.

nous
ne prévoyez pas verser de dividendes en espèces dans un avenir prévisible. Sauf pour ses actions privilégiées de classe B, le paiement de
dividendes est à la discrétion de notre conseil d’administration et dépendra de nos bénéfices, de nos besoins en capital, de nos
condition et d’autres facteurs pertinents. Aucune restriction ne limite actuellement notre capacité à verser des dividendes sur nos actions communes.
actions autres que celles généralement imposées par la loi en vigueur.

Titres
Autorisé pour émission dans le cadre de régimes de rémunération en actions

nous
n’ont pas actuellement, ou envisagent d’avoir, dans un proche avenir, un plan d’incitation aux actions.

Récent
Ventes de titres non inscrits

le
Vous trouverez ci-dessous un résumé des transactions effectuées depuis notre précédente publication sur notre formulaire 10-Q, déposé auprès de la Securities and Exchange Commission.
14 novembre 2018, impliquant la vente de nos titres qui n’étaient pas enregistrés en vertu de la loi intitulée Securities Act of 1933, dans sa version modifiée (la
«Securities Act»). Chaque offre et vente étaient dispensées d’inscription en vertu de l’article 4 (a) (2) de la loi sur les valeurs mobilières.
Loi ou la règle 506 (b) en vertu de la règle D de la loi sur les valeurs mobilières.

De
2 octobre 2018 au 7 novembre 2018, la Société a émis au total 13 094 733 actions ordinaires de CANB à RedDiamond en échange de
pour le départ à la retraite de 101 736 actions d’actions privilégiées de série B de CANB.

De
Du 5 novembre 2018 au 28 décembre 2018, la Société a émis un total de 2 125 000 actions ordinaires de CANB à plusieurs consultants.
pour les services rendus. La juste valeur de 80 665 $ des 2 125 000 actions ordinaires de CANB a été partiellement imputée à Consulting
honoraires pour la période de trois mois terminée le 30 décembre 2018.

De
Du 3 décembre 2018 au 28 décembre 2018, la Société a émis environ 1 500 000 actions ordinaires de CANB à trois membres du conseil
pour les services rendus. La juste valeur de 62 342 $ des 1 500 000 actions ordinaires de CANB a été imputée aux jetons de présence dans le
trois mois clos le 30 décembre 2018.

De
Du 3 décembre 2018 au 28 décembre 2018, la Société a émis au total 22 413 794 actions ordinaires de CANB à plusieurs investisseurs.
aux termes de conventions d’achat d’actions relatives datées à diverses dates, en échange d’un produit total de 650 000 $.

Sur
11 décembre 2018, la Société a émis 891 089 actions ordinaires de CANB à RedDiamond en paiement du dividende payable de
9 000 $.

Sur
Le 19 décembre 2018, la Société a émis 891 089 actions ordinaires de CANB à Auctus, LLC dans le cadre d’un exercice d’achat d’actions sans numéraire.
options.

Sur
Le 21 décembre 2018, la société a reçu un avis de conversion d'un prêteur. Par conséquent, 9 372 100 actions ordinaires de CANB ont été
émises au prêteur en règlement de billets d'un montant de 83 500 $ et d'intérêts courus de 10 221 $.

Sur
21 décembre 2018, la société a émis un total de 4 370 629 actions ordinaires de CANB à quatre dirigeants et dirigeants clés du
Société en règlement d’une indemnité cumulée de 192 300 $.

Sur
Le 28 décembre 2018, la Société a émis 3 096 827 actions ordinaires de CANB pour l’acquisition de Pure Health Products, LLC.

Sur
Le 28 décembre 2018, la Société a émis 245 789 actions ordinaires de CANB à un dirigeant clé de la Société en vertu du Code du travail.
Convention en date du 29 décembre 2018 avec Andrew Holtmeyer. La juste valeur de 14 207 $ de l’émission a été imputée à la rémunération à base d’actions
au cours des trois mois clos le 31 décembre 2018.

Sur
Le 29 décembre, la Société a émis 30 000 000 d’actions ordinaires de CANB à Marco Alfonsi en échange du retour de 3 actions.
des actions privilégiées de série A de CANB, propriété de Marco Alfonsi.

Sur
Le 28 janvier 2019, la Société a émis 10 000 000 d’actions ordinaires de CANB à un consultant de la Société en échange de la
restitution d'une action de la série d'actions privilégiées de série A de CANB.

De
21 février 2019 au 12 mars 2019, la Société a émis au total 20 221 436 actions ordinaires de CANB à RedDiamond en échange de
for the retirement of 157,105 shares of CANB Series B Preferred Stock.

De
January 4, 2019 to March 27, 2019, the Company issued aggregately 41,431,994 shares of CANB common stock to multiple investors
pursuant to relative Stock Purchase Agreements dated on various dates, in exchange for total proceeds of $1,196,100.

Sur
January 14, 2019, the Company issued 7,500,000 shares of CANB common stock the owner of Hudilab, Inc., pursuant to a License and
Acquisition Agreement dated January 14, 2019.

De
January 18, 2019 to March 17, 2019, the Company issued aggregately 24,600,000 shares of CANB common stock to multiple consultants
for services rendered.

De
January 19, 2019 to March 27, 2019, the Company issued aggregately 1,167,959 shares of CANB common stock to key employees and
officers of the Company pursuant to employee agreement and in satisfaction of accrued compensation for the quarter ended March
31, 2019.

Sur
February 5, 2019, the Company issued 2,000,000 shares to the owner of TZ Wholesale LLC, pursuant to a Memorandum of Understanding
(the “MOU”) dated November 9, 2018.

Sur
February 20, 2019, the Company issued 1,000,000 shares of CANB common stock to owners of Seven Chakras pursuant to an Asset Purchase
Agreement dated January 31, 2019.

Item 6.
    Selected Financial Data

ne pas
required for smaller reporting companies.

Item 7.
    Management’s Discussion and Analysis of Financial Condition
    and Results of Operation

General

Canbiola,
Inc. was originally formed as a Florida corporation on October 11, 2005, under the name of WrapMail, Inc. Effective January 5,
2015, we acquired 100% ownership of Prosperity Systems, Inc., which the Company is in the process of dissolving. Effective December
28, 2018, we acquired 100% ownership of Pure Health Products. In November 2018, we formed Duramed as a wholly-owned subsidiary.
The Company is presently in the process of dissolving Prosperity.

nous
manufacture and sell products containing CBD. We also provide document, project, marketing and sales management systems to our
residual business clients through our website and proprietary software, which divisions are being wound-down. The consolidated
financial statements include the accounts of CANB and its wholly owned subsidiary Pure Health Products from the date of its acquisition
on December 28, 2018.

Résultats
of Operations

Year
Ended December 31, 2018 compared with Year Ended December 31, 2017:

Revenues
increased $545,857 from $122,746 in 2017 to $668,603 in 2018. The increase was due to the growth of CBD product sales.

Coût
of product sales increased $361,068 from $44,466 in 2017 to $405,434 in 2018 due to the growth of product sales and outreach into
additional market segments such as wholesale and private label opportunities.

Officers
and director’s compensation and payroll taxes increased $1,324,581 from to $154,406 in 2017 to $1,478,987 in 2018. The 2017
expense amount ($154,406) consists of salaries accrued to our Chief Executive Officer ($84,000) and stock based compensation of
($63,902) pursuant to their respective employment agreements and related payroll taxes ($6,504). The 2018 expense amount ($1,478,987)
includes additional stock-based compensation of ($1,255,193) pursuant to their respective employment agreements and related payroll
taxes ($2,559).

Consulting
fees increased $1,384,902 from $284,741 in 2017 to $1,669,443 in 2018. The 2017 expense amount ($284,741) includes stock-based
compensation of ($167,688), resulting from stock issued for the service of consultants. The 2018 expense amount ($1,669,443) includes
stock-based compensation of ($1,527,107), resulting from stock issued for the service of consultants.

La publicité
expense increased $55,994 from $28,322 in 2017 to $84,316 in 2018.

Hosting
expense decreased $7,266 from $21,963 in 2017 to $14,697 in 2018.

Location
expense increased $2,105 from $65,060 in 2017 to $67,165 in 2018.

Professionnel
fees increased $22,172 from $95,546 in 2017 to $117,718 in 2018.

Dépréciation
of property and equipment increased $2,246 from $3,227 in 2017 to $5,473 in 2018.

Amortization
of intangible assets decreased $3,972 from $3,972 in 2017 to $0 in 2018.

Autre
operating expenses increased $107,215 from $133,829 in 2017 to $241,044 in 2018. The increase was due largely to higher commission
fees, supplies expense and shipping expenses in 2018 compared to 2017.

Net
loss increased $1,972,558 from $2,139,719 in 2017 to $4,112,277 in 2018. The increase was due to the $2,877,777 increase in total
operating expenses offset by the $730,430 decrease in other expense – net, and by the $184,989 increase in gross profit.

Liquidité
and Capital Resources

À
December 31, 2018, the Company had cash and cash equivalents of $807,747 and a working capital of $939,582. Trésorerie et équivalents de trésorerie
increased $806,095 from $1,652 at December 31, 2017 to $807,747 at December 31, 2018. For the year ended December 31, 2018, $1,605,644
was provided by financing activities, $753,569 was used in operating activities, and $45,980 was used in investing activities.

le
Company currently has no agreements, arrangements or understandings with any person to obtain funds through bank loans, lines
of credit or any other sources.

nous
currently have no commitments with any person for any capital expenditures.

nous
have no off-balance sheet arrangements.

Article
    7A.
    Quantitative
    and Qualitative Disclosure About Market Risk

ne pas
applicable.

Article
    8
    Financier
    Statements and Supplementary Data

Notre
Consolidated Financial Statements and Notes thereto, for the fiscal years ended December 31, 2018 and 2017 and the report of BMKR,
LLP, our independent registered public accounting firm, are set forth on pages F-1 through F-27 of this Annual Report.

Article
    9
    Changes
    in and Disagreements with Accountants on Accounting and Financial Disclosure

ne pas
applicable.

Article
    9A.
    Les contrôles
    and Procedures

Évaluation
of Disclosure Controls and Procedures

Divulgation
controls and procedures are designed to ensure that information required to be disclosed in the reports filed or submitted under
the Exchange Act is recorded, processed, summarized and reported, within the time period specified in the SEC’s rules and
forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information
required to be disclosed in the reports filed under the Exchange Act is accumulated and communicated to management, including
the Chief Executive Officer (CEO), as appropriate, to allow timely decisions regarding required disclosure. Based on the evaluation,
the CEO has concluded that our disclosure controls and procedures are ineffective to ensure that information disclosed by us in
the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified
in Securities and Exchange Commission rules and forms. This determination was based on the small size of our accounting staff,
the lack of segregation of duties and the lack of an audit committee.

À
address the material weaknesses, we performed additional analysis and other post-closing procedures in an effort to ensure our
financial statements included in this annual report have been prepared in accordance with generally accepted accounting principles.
Accordingly, management believes that the financial statements included in this report fairly present in all material respects
our financial condition, results of operations and cash flows for the periods presented.

Management
Report on Internal Control over Financial Reporting

Notre
management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control
system was designed to provide reasonable assurance to our management and board of directors regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

Any
internal control system, no matter how well designed, has inherent limitations and may not prevent or detect misstatements. En conséquence,
even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation
and presentation.

Management,
with the participation of our Chief Executive Officer, has evaluated the effectiveness of our internal control over financial
reporting as of December 31, 2018 based on criteria established in Internal Control—Integrated Framework issued by the Committee
of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, because of the Company’s limited resources
and limited number of employees, and the absence of an audit committee, management concluded that, as of December 31, 2018, our
internal control over financial reporting is not effective in providing reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting
principle, which creates a material weakness. A material weakness is a deficiency, or a combination of deficiencies, in internal
control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s
annual or interim financial statements will not be prevented or detected on a timely basis. A material weakness means there is
a risk that our financial reports or other filings may contain an error or inaccuracy or not submitted timely.

Là
was a material weakness in the Company’s internal control over financial reporting due to the fact that the Company did
not have an adequate process established to ensure appropriate levels of review of accounting and financial reporting matters,
which resulted in our closing process not identifying all required adjustments and disclosures in a timely fashion. We expect
that the Company will need to hire accounting personnel with the requisite knowledge to improve the levels of review of accounting
and financial reporting matters. The Company may experience delays in doing so and any such additional employees would require
time and training to learn the Company’s business and operating processes and procedures. For the near-term future, until
such personnel are in place, this will continue to constitute a material weakness in the Company’s internal control over
financial reporting that could result in material misstatements in the Company’s financial statements not being prevented
or detected.

Changes
in Internal Control over Financial Reporting

Là
have been no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f)
under the Securities and Exchange Act of 1934) during the year ended December 31, 2018 that have materially affected, or are reasonably
likely to materially affect, our internal control over financial reporting.

Article
    9B.
    Autre
    Information

None.

PART
III

Article
    dix.
    Directors,
    Executive Officers and Corporate Governance

Notre
board of directors is elected annually by our shareholders. The board of directors elects our executive officers annually. Notre
directors and executive officers as of April __, 2019 are as follows:

prénom
    
    Âge
    
    Position

    Marco
    Alfonsi
    
    57
    
    CEO,
    Director, Chairman

    Stanley
    L. Teeple
    
    70
    
    CFO,
    Secretary, Director

    Andrew
    Holtmeyer
    
    57
    
    VP
    of Business Development

Marco
Alfonsi, CEO and Chairman Director has been a financial service professional for the past 20 years. Mr. Alfonsi was appointed
director and CEO of the Company in or around January 2015. Immediately prior to that, he spent eight years serving as the CEO
of Prosperity Systems, Inc.

Throughout
his career, Mr. Alfonsi was directly and indirectly involved in raising over $100 million dollars for small and medium sized business.
Prior to his involvement in the financial services industry, Mr. Alfonsi has owned, operated, financed and sold several businesses.
Mr. Alfonsi successfully started and managed two companies (ExecuteDirect.com, and Bakers Express of New York, Inc.), and held
senior management positions with a number of financial institutions, including: Global American Investments, Clark Street Capital
and Basic Investors.

Stanley
L. Teeple –Mr. Teeple was engaged from 2017-2018 with Solis Tek, Inc. (OTCQB:SLTK) a California based publicly traded
corporation as Senior Vice President, Corporate Secretary, and Chief Compliance Officer. Solis Tek, Inc. a NV Corporation, is
a developer of lighting and nutrient products, and most recently in cultivation and processing for the cannabis industry. Précédemment,
from 2015-2016 Mr. Teeple was Chief Financial Officer and Secretary for Zonzia Media, Inc. (OTC:ZONX), a provider of streaming
video and content to cable subscribers and hotel networks throughout the eastern US. From 2008 to 2014 Mr. Teeple was Chief Financial
Officer and Secretary of Indigo-Energy, Inc. (OTC:IDGG) a publicly traded company in the oil and gas exploration business. Plus de
the prior three plus decades Mr. Teeple through his turnaround consulting business, Stan Teeple, Inc., has held numerous senior
management positions in several public and private companies across a broad spectrum of industries. Additionally, he has operated
and worked for various court appointed trustees and principals as CEO, COO, and CFO in the entertainment, pharmaceuticals, food,
travel, and tech industries. He operated his consulting business on a project-to-project basis and holds various other directorships.
His businesses operational strengths include knowing how to manage and maximize the resources and preserve the integrity of a
company from start-up through to maturity and corporate compliance in a regulatory environment.

Andrew
Holtmeyer – Mr. Holtmeyer started his business career in the financial services sector. During his 20 year career on
wall street, Mr. Holtmeyer worked at and built several investment firms that employed hundreds of salesmen. During the last 5
years of his career, he concentrated mostly on investment banking. After leaving the financial sector, Mr. Holtmeyer started a
highly successful consulting firm, which concentrated on raising capital for small to mid-sized companies that were both private
and public. After selling his consulting business, Mr. Holtmeyer started a very successful real estates business which is now
run by his family.

Carl
Dilley, 63, served on our Board of Directors until he resigned for personal reasons on February 21, 2019.

David
Posel, 39, served as the Company’s COO during 2018, when the Company’s operations were limited to its contractual
arrangement with Pure Health Products. After acquiring PHP directly, Mr. Posel was transitioned to COO of PHP.

Board
Committees

nous
have not yet established an audit committee, compensation committee, or nominating committee. During 2018, the functions ordinarily
handled by these committees were handled by our entire Board.

Famille
Relationships

Là
are no familial relationships between any of our officers and directors.

Réalisateur
or Officer Involvement in Certain Legal Proceedings

Notre
current directors and executive officers have not been involved in any legal proceedings as described in Item 401(f) of Regulation
S-K in the past ten years.

Réalisateur
Independence

le
Company is not currently listed on any national securities exchange that has a requirement that the board of directors be independent.
None of the Company’s directors are independent.

Code
of Ethics

nous
have not adopted a Code of Ethics that applies to all of our employees and officers, and the members of our Board of Directors
due to the financial constraints of doing so.

Section
16(a) Beneficial Ownership Reporting Compliance

Section
16(a) of the Exchange Act requires our directors and executive officers, and persons who own more than 10% of a registered class
of our equity securities, to file reports of ownership and changes in ownership with the SEC. Officers, directors and greater
than 10% shareholders are required by SEC regulation to furnish the Company with copies of all Section 16(a) forms they file.
Based on our review of the reports filed by Reporting Persons, we believe that, during the year ended December 31, 2018, the following
Reporting Persons did not meet all applicable Section 16(a) filing requirements: (i) Stanley Teeple, (ii) David Posel, and (iii)
Carl Dilley. Otherwise, we believe that the Reporting Persons met such filing requirements.

Article
    11
    Exécutif
    Compensation

le
table below summarizes all compensation awarded to, earned by, or paid to our executive officers and directors for all services
rendered in all capacities to us during the previous two fiscal years, as of December 31, 2018.

Exécutif
    Summary Compensation Table

    prénom
    and principal position 
    Year  
    Un salaire
    Prime
    Stock
    prix
    Option
    prix
    Non-equity
    incentive plan compensation  
    Non-qualified
    deferred compensation earnings  
    Tout
    autre compensation
    Total

    Marco Alfonsi(1) 
    2017
    $84,000  
    $    0  
    $63,902  
    0 $
    $               0  
    $            0  
    $                0  
    $147,902 

    CEO and Director 
    2018
    $104,500  
    0 $
    0 $
    0 $
    0 $
    0 $
    0 $
    $104,500 

    Stanley L. Teeple(2) 
    2018
    $45,000  
    0 $
    $144,500  
    $118,200  
    0 $
    0 $
    0 $
    $307,700 

    Andrew Holtmeyer(3) 
    2018
    $118,400  
    0 $
    $  1,169,658  
    0 $
    0 $
    0 $
    0 $
    $  1,288,058 

    David Posel (4) 
    2018
    $60,000  
    0 $
    $58,720  
    0 $
    0 $
    0 $
    0 $
    $118,720

(1)
Pursuant to an employment agreement entered on or around May 14, 2015, Marco Alfonsi was entitled to receive compensation of $6,000
per month through September 31, 2017 when the contract expired. On or around October 3, 2017, the Company entered into a new employment
agreement with Mr. Alfonsi whereby he was entitled to receive $10,000 per month for a period of three years. Mr. Alfonsi also
received one share of Class A Preferred Stock upon his execution of the new agreement. In addition, on or around October 4, 2017,
the Company authorized the issuance of an additional two shares of Class A Preferred Stock to Mr. Alfonsi in consideration for
cancellation of approximately $120,000 of deferred income owed to Mr. Alfonsi. The Company entered into a new employment agreement
dated October 21, 2018 Mr. Alfonsi, pursuant to which Mr. Alfonsi agreed to continue to serve as the Company’s Chief Executive
Officer (“CEO”) and accept appointment as Chairman of the Board of Directors (“Chairman”) for an initial
term of four (4) years. He is entitled to receive $15,000 per month and other compensation under the new agreement.

(2)
Pursuant to an employment agreement entered on or around October 15, 2018, Mr. Teeple services as the Company’s Chief Financial
Officer and Secretary for a term of 4 years. The Agreement also provides for compensation to Mr. Teeple of $15,000 cash per month
and the issuance of 1 share of Series A Preferred Stock upon execution of the Agreement. The fair value of the Series A preferred
Stock is $578,000 and has a vesting period of four years. In 2018, the amortized portion of Series A preferred Stock is $144,500.

(3)
On February 16, 2018, the Company executed an Executive Service Agreement (“Agreement”) with Andrew W Holtmeyer. le
Agreement provides that Mr. Holtmeyer services as the Company’s Executive Vice President Business for a term of 3 years.
The Agreement also provides for compensation to Mr. Holtmeyer of $10,000 cash per month and the issuance of 3, 2 and 1 share of
Series A Preferred Stock at the beginning of each year. On December 29, 2018, this Agreement was terminated due to the execution
of a new Employment Agreement with Andrew W Holtmeyer. The Agreement provides that Mr. Holtmeyer services as the Company’s
Executive Vice President Business for a term of 4 years. The Agreement also provides for compensation to Mr. Holtmeyer of $15,000
cash per month and the issuance of 245,789 shares of common stock upon signing of the agreement. In 2018, the Company issued 5
shares of Series A preferred shares valued at $3,910,000 and the amortization in 2018 is $1,169,658.

(4)
On February 12, 2018, the Company executed an Executive Service Agreement (“Agreement”) with David Posel. The Agreement
provides that Mr. Posel services as the Company’s Chief Operating Officer for a term of 4 years. The Agreement also provides
for compensation to Mr. Posel of $5,000 cash per month and the issuance of 1 share of Series A Preferred Stock at the inception
of the Agreement. In the fourth quarter, this Agreement was terminated due to the execution of a new Employment Agreement between
Pure Health Products, LLC and David Posel. The fair value of the Series A preferred Stock is $373,000 and has a vesting period
of four years. In 2018, the amortized portion of Series A preferred Stock related to Mr. Posel’s service as an executive
is $58,720.

nous
do not have an equity incentive plan and no named executive officer has unexercised outstanding equity awards.

le
table below summarizes all compensation awarded to, earned by, or paid to our non-interested directors for all services rendered
in all capacities to us during the previous two fiscal years, as of December 31, 2018.

Non-Interested
    Director Summary Compensation Table

    prénom
    and principal position 
    Year 
    Fees
    Earned or Paid in Cash  
    Stock
    prix
    Option
    prix
    Non-equity
    incentive plan compensation  
    Non-qualified
    deferred compensation earnings  
    Tout
    autre compensation
    Total

    Carl Dilley(1) 
    2017
    0 $
    0 $
    0 $
    0 $
    0 $
    0 $
    0 $

    Réalisateur
    2018
    0 $
    0 $
    $84,000  
    0 $
    0 $
    0 $
    $84,000

(1)
    M.
    Dilley resigned from the Company on February 21, 2019.

Non
director has received cash compensation for their directorship. We do not have a compensation committee and compensation for our
directors and officers is determined by our board of directors.

nous
reimburse Non-Employee Directors for actual out-of-pocket costs incurred to attend board meetings. No additional compensation
is paid for attendance in person or by telephone at board meetings.

Article
    12
    Sécurité
    Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

le
following tables set forth the ownership, as of April 12, 2019, of our common stock by each person known by us to be the beneficial
owner of more than 5% of our outstanding voting stock, our directors, and our executive officers and directors as a group. À
the best of our knowledge, the persons named have sole voting and investment power with respect to such shares, except as otherwise
noted. There are not any pending or anticipated arrangements that may cause a change in control. The Company’s principal
office is the business address for each of the named shareholders.

Là
are 548,487,714 shares of common stock outstanding as of April 12, 2019, and 17 shares of Series A preferred stock issued and
outstanding, which in aggregate are convertible into 170,000,000 shares of common stock at any time and represent 340,000,000
votes. There is a total of approximately 888,487,714 votes eligible to be cast in any Company vote as of April 15, 2019.

Sur
April 12, 2019, Red Diamond Partners LLC (“Red Diamond”) owned 342,853 shares of Series B Preferred Stock, which is
convertible into approximately 44,129,594 shares of common stock, subject to ownership percentage limitations; however, Series
B Preferred Stock is non-voting.

le
information presented below regarding beneficial ownership of our voting securities has been presented in accordance with the
rules of the Securities and Exchange Commission and is not necessarily indicative of ownership for any other purpose. Under these
rules, a person is deemed to be a “beneficial owner” of a security if that person has or shares the power to vote
or direct the voting of the security or the power to dispose or direct the disposition of the security. A person is deemed to
own beneficially any security as to which such person has the right to acquire sole or shared voting or investment power within
60 days through the conversion or exercise of any convertible security, warrant, option or other right. More than one person may
be deemed to be a beneficial owner of the same securities.

Sauf
as otherwise indicated and under applicable community property laws, we believe that the beneficial owners of our common stock
listed below have sole voting and investment power with respect to the shares shown. Unless stated otherwise, the business address
for these shareholders is 960 South Broadway, Suite 120, Hicksville NY 11801.

prénom
    Titre
    Nombre
    of Common Shares  
    %
    of Common Shares  
    Nombre
    of Series A Preferred Shares  
    %
    of Series A Preferred Shares  
    %
    of Eligible Votes  
    Nombre
    of Warrants currently exercisable or exercisable in the next 60 days 

    Marco Alfonsi(1) 
    CEO, Director 
     59,398,915  
     10.83% 
    5
     29.41% 
     17.94% 
    0

    Stanley L. Teeple(2) 
    CFO, Director 
     980,752  
     0.18% 
    1
     5.88% 
     2.36% 
    0

    Andrew Holtmeyer(3) 
    Vice président
     1,107,769  
     0.20% 
    5
     29.41% 
     11.38% 
    0

    All officers and directors as a group
    (3 persons) 
    
     61,487,436  
     11.21% 
    11
     64.70% 
     31.68% 
    0

(1)
As of April 12, 2019, Marco Alfonsi owns approximately 59,398,915 shares of common stock and 5 shares of Series A preferred stock,
which are convertible into 50,000,000 shares and equal 100,000,000 votes. Prior to October 29, 2015, Mr. Alfonsi owned 81,000,000
shares of the Company’s common stock, at which time it was agreed that he would retire 50,000,000 shares of common stock
for 5 shares of Series A Preferred Stock. In addition to the listed shares, four members of Mr. Alfonsi’s family hold an
aggregate of 10,000,000 shares of common stock, which shares have not been included in the above calculations.

(2)
As of April 12, 2019, Stanley L. Teeple owns approximately 980,752 shares of common stock and 1 shares of Series A preferred stock,
which are convertible into 10,000,000 shares and equal 20,000,000 votes.

(3)
As of April 12, 2019, Andrew Holtmeyer owns approximately 1,107,769 shares of common stock and 5 shares of Series A preferred
stock, which are convertible into 50,000,000 shares and equal 100,000,000 votes.

le
following tables set forth the ownership of our common stock by each person known by us to be the beneficial owner of more than
5% of our outstanding voting stock, excluding our directors and our executive officers

prénom
    Nombre
    of Common Shares  
    %
    of Common Shares  
    Nombre
    of Preferred A Shares  
    %
    of Shares  
    %
    of Eligible Votes  
    Nombre
    of Warrants currently exercisable or exercisable in the next 60 days 

    McKenzie Webster Limited(1) 
     64,879,916  
     11.83% 
    0
    0%
     7.30% 
    0

    Pasquale Ferro (2) 
     22,172,159  
    4,04%
    5
     29.41% 
     13.75% 
    0

(1)
    McKenzie
    Webster Limited is controlled by the Company’s former director and CFO, Rolv Heggenhougen. The business address for
    this shareholder is 445 NE 12th Ave., Fort Lauderdale, Florida 33301.

    
    (2)
    Pasquale
    Ferro is the President of Pure Health Products, LLC, a wholly owned subsidiary of the Company.

le
above tables are based upon information derived from our stock records. Except as otherwise indicated below and under applicable
community property laws, we believe that the beneficial owners of our common stock listed below have sole voting and investment
power with respect to the shares shown.

Article
    13
    Certain
    Relationships and Related Party Transactions

Sauf
as described herein (or within the section entitled Executive Compensation of this prospectus), none of the following parties
(each a “Related Party”) has, in our fiscal years ended 2017 and 2018, had any material interest, direct or indirect,
in any transaction with us or in any presently proposed transaction that has or will materially affect us:

●
    tout
    of our directors or officers;

    ●
    tout
    person who beneficially owns, directly or indirectly, shares carrying more than 10% of the voting rights attached to our outstanding
    shares of common stock; ou

    ●
    tout
    member of the immediate family (including spouse, parents, children, siblings and in- laws) of any of the above persons.

ProAdvanced
Group, Inc. (“PAG”), an entity controlled by the Company’s chief executive officer, is a customer of CANB. À
December 31, 2018, CANB had an account receivable from PAG of $7,240. For the year ended December 31, 2018, CANB had revenues
from PAG of $5,000.

Île
Stock Transfer (“IST”), an entity controlled by Carl Dilley, a Company director, is both a customer and vendor of
CANB. At December 31, 2018, CANB had an account receivable from IST of $7,035 and an account payable to IST of $1,454. Pour le
year ended December 31, 2018, CANB had revenues from IST of $4,000.

Stock
Market Manager, Inc. is also an entity controlled by Mr. Dilley. For the year ended December 31, 2018, CANB had an account payable
to Stock Market Manager Inc. of $1,676.

Dans
order to facilitate its operations, the Company has entered into a Production Agreement with Pure Health Products, LLC (“PHP”),
a New York limited liability company. Pursuant to the Production Agreement, PHP will manufacture, package, and sell the Company’s
CBD infused products on an exclusive basis. PHP will not produce or manufacture any product containing any cannabis or hemp derivative
for any person or entity other than the Company, and the Company controls the ingredients, recipe, manufacturing processes and
procedures and quality and taste parameters for all Products produced at the PHP facility. PHP may also white label / rebrand
or relabel the products on the Company’s behalf pursuant to “white label agreements” entered into between the
Company and third-party customers. Credit card sales are processed through PHP as well. Through its contractual relationship with
PHP, the Company is able to control the manufacturing process of its products while reducing its production costs. En outre,
the Company has the option to acquire certain assets of PHP should it elect to take over direct manufacture of its Products. Pour
the year ended December 31, 2018, purchase of CBD infused products from PHP totaled $274,556.50. Effective December 28, 2018,
the Company acquired Pure Health Products, LLC.

During
the year ended December 31, 2018, we had products and service sales to related parties totaling $5,000.

Article
    14
    Principal
    Accounting Fees and Services

le
following table sets forth fees billed to us by BMKR, LLP, our independent registered public accounting firm, during the fiscal
years ended December 31, 2018 and December 31, 2017 for: (i) services rendered for the audit of our annual financial statements
and the review of our quarterly financial statements; (ii) services by our independent registered public accounting firms that
are reasonably related to the performance of the audit or review of our financial statements and that are not reported as audit
fees; (iii) services rendered in connection with tax compliance, tax advice and tax planning; and (iv) all other fees for services
rendered.

décembre
    31, 2018  
    décembre
    31, 2017 

    Audit Fees 
    $23,965  
    $31,700 

    Audited Related Fees 
    $
    $

    Tax Fees 
    $
    $

    All Other Fees 
    $
    $

PART
IV

Article
    15
    Exhibits,
    Financial Statement Schedules.

Exhibits
Programme

le
following exhibits are filed with this Annual Report:

*
    classé
    with the Form S-1 Registration Statement filed with the SEC on December 2, 2015 and incorporated herein by reference.

    **
    previously filed

SIGNATURES

Dans
accordance with Section 13 or 15(d) of the Exchange Act, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.

Canbiola,
    Inc.

    Rendez-vous amoureux:
    17 avril 2019
    Par:
    /s/
    Marco Alfonsi

    
    Prénom:
    Marco
    Alfonsi

    
    Titre:
    Chef
    Executive Officer

    
    
    (Principal
    Executive Officer and Principal Accounting Officer)

Dans
accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in
the capacities and on the dates indicated.

Person
    
    Capacité
    
    Rendez-vous amoureux

    /s/
    Marco Alfonsi
    
    Réalisateur
    
    avril
    17, 2019

    Marco
    Alfonsi
    
    
    
    

    /s/
    Stanley L. Teeple
    
    Réalisateur
    
    avril
    17, 2019

    Stanley
    L. Teeple

CANBIOLA,
INC. AND SUBSIDIARY

Index
to Financial Statements

BMKR,
    LLP

Agréé
    Public Accountants
    

    T
    631 293-5000

    1200
    Veterans Memorial Hwy., Suite 350

    F
    631 234-4272

    Hauppauge,
    New York 11788

www.bmkr.com

Thomas
    G. Kober, CPA

Charles
                                         W. Blanchfield, CPA (Retired)

Alfred
                                         M. Rizzo, CPA

Bruce
    A. Meyer, CPA (Retired)

    Joseph
    Mortimer. CPA

REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

À
the Board of Directors and

Stockholders
of Canbiola, Inc

Opinion
on the Financial Statements

nous
have audited the accompanying consolidated balance sheets of Canbiola Inc. (the Company) as of December 31. 2018 and 2017, and
the related consolidated statements of operations, consolidated stockholders’ equity. and cash flows for each of the years
in the two year period ended December 31, 2018, and the related notes (collectively referred to as the financial statements).
In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of
December 31, 2018 and 2017, and the results of its operations and its cash flows for each of the years in the two year period
ended December 31, 2018, in conformity with accounting principles generally accepted in the United States of America.

Base
for Opinion

Celles-ci
financial statements are the responsibility of the Company’s management. Our responsibility is to express an opm1on on the
Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting
Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the
U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

nous
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit
to obtain reasonable assurance about whether the financial statements are tree of material misstatement, whether due to error
or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its intemal control over financial
reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but
not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting.
Accordingly, we express no such opinion.

Notre
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to
error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles
used and significant estimates made by management as well as evaluating the overall presentation of the financial statements.
We believe that our audits provide a reasonable basis for our opinion.

Going
Concern

le
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As shown in the
financial statements, the Company incurred a net loss of $4,112,277 during the year ended December 31, 2018, and as of that date,
had an accumulated deficit of $18,768,753 The company is in arears with certain vendor creditors which, among other things, cause
the balances to become due on demand. The Company is not aware of any alternate sources of capital to meet such demands, if made.

Comme
discussed in note 2 to the financial statements, the Company’s significant operating losses raise substantial doubt about
its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the
outcome of this uncertainty. Our opinion is not modified with respect to that matter.

nous
have served as the Company’s auditor since 2014. Hauppauge,

New York

avril
15, 2019

Membre
American Institute of Certified Public Accounts

Membre
Public Company Accounting Oversight Board

Canbiola,
Inc. and Subsidiary

Consolidé
Balance Sheets

décembre
    31, 2018  
    décembre
    31, 2017 

    Assets 
    
    

    Current assets: 
    
    

    En espèces
    and cash equivalents 
    $807,747  
    $1,652 

    Accounts receivable,
    less allowance for doubtful accounts of $0 and $0, respectively 
     39,172  
     6,075 

    Inventaire
     87,104  
     9,834 

    Note receivable
    – current 
    –
     75,000 

    Prepaid
    expenses – current 
     210,351  
     64,911 

    Total
    actifs courants
     1,144,374  
     157,472 

    Property and
    equipment, at cost less accumulated depreciation of $26,775 and $20,248, respectively 
     59,619  
     11,148 

    Other assets: 
    
    

    Dépôts
     48,726  
     11,687 

    Prepaid expenses
    – noncurrent 
     2,365,719  
    –

    Note receivable
    – noncurrent 
     19,389  
     39,000 

    Bonne volonté
    (Note 4) 
     55,849  
    –

    Total
    autres actifs
     2,489,683  
     50,687 

    Total des actifs
    $3,693,675  
    $219,307 

    Les passifs
    and Stockholders’ Deficiency 
    
    

    Passif à court terme:
    
    

    Notes and loans
    payable
    $19,205  
    $193,504 

    Derivative Liability 
    –
     1,451,137 

    Comptes à payer
     73,059  
     143,274 

    Accrued officers
    compensation
     68,750  
     98,750 

    Autre
    charges à payer
     43,778  
     62,539 

    Total
    current liabilities and total liabilities 
     204,792  
     1,949,204 

    Commitments and contingencies (Notes
    14) 
    
    

    Stockholders’ deficiency: 
    
    

    Preferred stock,
    authorized 5,000,000 shares: 
    
    

    Series A Preferred
    stock, no par value: authorized 20 shares, issued and outstanding 18 and 8 shares, respectively 
     4,557,424  
     243,537 

    Series B Preferred
    stock, $0.001 par value: authorized 500,000 shares, issued and outstanding 499,958 and 157,985 shares, respectively 
    479
    150

    Common stock, no
    par value; authorized 750,000,000 shares, issued and outstanding 440,566,325 and 225,572,323 shares, respectively 
     16,624,557  
     12,524,042 

    Additional Paid-in
    Capitale
     872,976  
     149,850 

    Additional Paid-in
    capital – Stock Options (Note 12) 
     202,200  
    –

    Accumulated
    déficit
     (18,768,753) 
     (14,647,476)

    Total stockholders’
    carence
     3,488,883  
     (1,729,897)

    Total liabilities
    and stockholders’ deficiency 
    $3,693,675  
    $219,307

Voir
notes to consolidated financial statements.

Canbiola,
Inc. and Subsidiary

Consolidé
Statements of Operations and Comprehensive Loss

Années
Ended December 31, 2018 and 2017

2018
    2017

    Revenues 
    
    

    Produit
    Sales 
    $651,978  
    $79,030 

    Un service
    Revenu
     16,625  
     43,716 

    Revenus totaux
     668,603  
     122,746 

    Coût
    of product sales 
     405,534  
     44,466 

    Gross Profit 
     263,069  
     78,280 

    Operating costs and expenses: 
    
    

    Officers and directors
    compensation (including stock-based compensation of $1,255,193 and $63,902 respectively) 
     1,478,987  
     154,406 

    Consulting fees
    (including stock-based compensation of $1,524,107 and $167,688, respectively) 
     1,669,443  
     284,741 

    Advertising expense 
     84,316  
     28,322 

    Hosting expense 
     14,697  
     21,963 

    Rent expense 
     67,165  
     65,060 

    Professional fees 
     117,718  
     95,546 

    Depreciation of
    property and equipment 
     5,473  
     3,227 

    Amortization of
    immobilisations incorporelles
    –
     3,972 

    Autre
     241,044  
     133,829 

    Total
    frais d'exploitation
     3,678,843  
     791,066 

    Loss from operations 
     (3,415,774) 
     (712,786)

    Other income (expense): 
    
    

    Cancellation of Debt 
    –
     10,589 

    Loss on Forgiveness
    of receivable from Pure Health Products 
     (85,827) 
    –

    Loss on debt conversion 
     (1,299,369) 
     (32,383)

    Loss on stock issuance 
     (649,259) 
     (191,553)

    Impairment of intangible
    les atouts
    –
     (21,507)

    Interest income 
     10,325  
     2,842 

    Income (expense)
    from derivative liability 
     1,591,137  
     (915,700)

    Intérêt
    expense (including amortization of debt discounts of $176,497 and $50,315, respectively) 
     (263,510) 
     (279,221)

    Autre
    income (expense) – net 
     (696,503) 
     (1,426,933)

    Loss before provision for income taxes 
     (4,112,277) 
     (2,139,719)

    Provision for
    impôts sur le revenu
    –
    –

    Net loss and
    comprehensive loss 
    $(4,112,277) 
    $(2,139,719)

    Net loss per
    common share – basic and diluted 
    $(.01) 
    $(.00)

    Weighted average common shares outstanding – 
    
    

    De base
     276,026,704  
     165,230,550 

    Dilué
     423,881,781  
     256,295,851

Canbiola,
Inc. and Subsidiary

Consolidé
Statements of Stockholders’ Deficiency

Années
Ended December 31, 2017 and 2018

Preferred Stock A,
    
    
    Preferred Stock B,
    
    
    Commun
Stock,
    
    
    Additionnel
    
    
    
    
    
    
    

    
    
    non
    par value
    
    
    $0.001
    par value
    
    
    non
    par value
    
    
    Paid-in
    
    
    Accumulated
    
    
    
    

    
    
    Actions
    
    
    Montant
    
    
    Actions
    
    
    Montant
    
    
    Actions
    
    
    Montant
    
    
    Capitale
    
    
    Deficit
    
    
    Total
    

    Balance,
    December 31, 2016
    
    
    dix
    
    
    $
    103,664
    
    
    
    –
    
    
    
    –
    
    
    
    146,008,250
    
    
    $
    11,889,505
    
    
    $
    –
    
    
    $
    (12,507,757
    )
    
    $
    (514,588
    )

    Issuance
    of common stock on February 2, 2017 for services rendered
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    200,000
    
    
    
    11,000
    
    
    
    
    
    
    
    
    
    
    
    11,000
    

    Issuance
    of common stock on February 13, 2017 in satisfaction of debt and accrued interest
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    1,685,900
    
    
    
    67,436
    
    
    
    
    
    
    
    
    
    
    
    67,436
    

    Issuance
    of common stock on March 22, 2017 in satisfaction of debt and accrued interest
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    6,785,316
    
    
    
    154,027
    
    
    
    
    
    
    
    
    
    
    
    154,027
    

    Issuance
    of common stock on April 17, 2017 for services rendered
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    5,000,000
    
    
    
    125 000
    
    
    
    
    
    
    
    
    
    
    
    125 000
    

    Issuance
    of common stock on June 21, 2017 for services rendered
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    250,000
    
    
    
    5,975
    
    
    
    
    
    
    
    
    
    
    
    5,975
    

    Issuance
    of common stock on June 28, 2017 for services rendered
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    250,000
    
    
    
    5 000
    
    
    
    
    
    
    
    
    
    
    
    5 000
    

    Issuance
    of common stock on August 25, 2017 in satisfaction of debt and accrued interest
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    7,142,857
    
    
    
    107,142
    
    
    
    
    
    
    
    
    
    
    
    107,142
    

    Issuance
    of common stock on August 25, 2017 for services rendered
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    250,000
    
    
    
    3,750
    
    
    
    
    
    
    
    
    
    
    
    3,750
    

    Issuance
    of common stock on September 5, 2017 for services rendered
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    250,000
    
    
    
    4,375
    
    
    
    
    
    
    
    
    
    
    
    4,375
    

    Issuance
    of common stock on September 7, 2017 for services rendered
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    2,500,000
    
    
    
    32,750
    
    
    
    
    
    
    
    
    
    
    
    32,750
    

    Issuance
    of common stock on September 11, 2017 for services rendered
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    500 000
    
    
    
    6,700
    
    
    
    
    
    
    
    
    
    
    
    6,700
    

    Issuance
    of common stock on September 25, 2017 for services rendered
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    250,000
    
    
    
    2,525
    
    
    
    
    
    
    
    
    
    
    
    2,525
    

    Issuance
    of Series A Preferred Stock on October 4, 2017 in satisfaction of accrued officer compensation
    
    
    3
    
    
    
    191,705
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    191,705
    

    Vente
    of Series B Preferred Stock on October 13, 2017 at $0.95 per share
    
    
    
    
    
    
    
    
    
    
    157,985
    
    
    
    150
    
    
    
    
    
    
    
    
    
    
    
    149,850
    
    
    
    
    
    
    
    150,000
    

    Issuance
    of common stock on November 2, 2017 for services rendered
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    250,000
    
    
    
    1,725
    
    
    
    
    
    
    
    
    
    
    
    1,725
    

    Issuance
    of common stock on November 9, 2017 for services rendered
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    2,500,000
    
    
    
    21,250
    
    
    
    
    
    
    
    
    
    
    
    21,250
    

    Issuance
    of common stock and retirement of Series A preferred stock on November 30, 2017
    
    
    (5
    )
    
    
    (51,832
    )
    
    
    
    
    
    
    
    
    
    
    50,000,000
    
    
    
    51,832
    
    
    
    
    
    
    
    
    
    
    
    –
    

    Issuance
    of common stock on December 5, 2017 for services rendered
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    500 000
    
    
    
    6,000
    
    
    
    
    
    
    
    
    
    
    
    6,000
    

    Issuance
    of common stock on December 7, 2017 for services rendered
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    250,000
    
    
    
    4 500
    
    
    
    
    
    
    
    
    
    
    
    4 500
    

    Issuance
    of common stock on December 18, 2017 for services rendered
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    500 000
    
    
    
    9,050
    
    
    
    
    
    
    
    
    
    
    
    9,050
    

    Issuance
    of common stock on December 25, 2017 for services rendered
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    500 000
    
    
    
    14,500
    
    
    
    
    
    
    
    
    
    
    
    14,500
    

    Net
    perte
    
    
    –
    
    
    
    –
    
    
    
    –
    
    
    
    –
    
    
    
    –
    
    
    
    –
    
    
    
    
    
    
    
    (2,139,719
    )
    
    
    (2,139,719
    )

    Balance,
    31 décembre 2017
    
    
    8
    
    
    $
    243,537
    
    
    
    157,985
    
    
    $
    150
    
    
    
    225,572,323
    
    
    $
    12,524,042
    
    
    $
    149,850
    
    
    $
    (14,647,476
    )
    
    $
    (1,729,897
    )

    Issuance
    of Series A Preferred Stock in
2018 pursuant to employment and
Accord de consultation
    
    
    13
    
    
    
    4,441,690
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    4,441,690
    

    Vente
    of Series B Preferred Stock in 2018
    
    
    
    
    
    
    
    
    
    
    761,972
    
    
    
    749
    
    
    
    
    
    
    
    
    
    
    
    723,126
    
    
    
    
    
    
    
    723,875
    

    Issuance
    of common stock in 2018 for services rendered
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    19,345,789
    
    
    
    656,306
    
    
    
    
    
    
    
    
    
    
    
    656,306
    

    Issuance
    of common stock in 2018 for Preferred B dividends
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    891,089
    
    
    
    38,379
    
    
    
    
    
    
    
    (9,000
    )
    
    
    29,379
    

    Issuance
    of common stock in 2018 in Satisfaction of debt and accrued interest
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    45,263,513
    
    
    
    1,604,412
    
    
    
    
    
    
    
    ,
    
    
    
    1,604,412
    

    Issuance
    of common stock in 2018 for Warrant exercise
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    8,500,000
    
    
    
    619,880
    
    
    
    
    
    
    
    
    
    
    
    619,880
    

    Issuance
    of common stock in 2018 in Satisfaction of accrued compensation
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    4,370,629
    
    
    
    192,300
    
    
    
    
    
    
    
    
    
    
    
    192,300
    

    Issuance
    of common stock in 2018 for Acquisition of PureHealth, LLC
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    3,096,827
    
    
    
    112,415
    
    
    
    
    
    
    
    
    
    
    
    112,415
    

    Issuance
    of stock options for retirement Of common shares
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (3,000,000
    )
    
    
    (101,400
    )
    
    
    84,000
    
    
    
    
    
    
    
    (17,400
    )

    Issuance
    of stock options
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    118,200
    
    
    
    
    
    
    
    118,200
    

    Vente
    of common stocks in 2018
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    29,821,201
    
    
    
    850,000
    
    
    
    
    
    
    
    
    
    
    
    850,000
    

    Issuance
    of common stock and retirement of Series A preferred stock In 2018
    
    
    (3
    )
    
    
    (127,803
    )
    
    
    
    
    
    
    
    
    
    
    30,000,000
    
    
    
    127,803
    
    
    
    
    
    
    
    
    
    
    
    –
    

    Issuance
    of common stock and retirement of Series B preferred stock In 2018
    
    
    
    
    
    
    
    
    
    
    (419,999
    )
    
    
    (420
    )
    
    
    76,704,954
    
    
    
    420
    
    
    
    –
    
    
    
    
    
    
    
    –
    

    Net
    perte
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (4,112,277
    )
    
    
    (4,112,277
    )

    Balance,
    31 décembre 2018
    
    
    18
    
    
    $
    4,557,424
    
    
    
    499,958
    
    
    $
    479
    
    
    
    440,566,325
    
    
    $
    16,624,557
    
    
    $
    1,075,176
    
    
    $
    (18,768,753
    )
    
    
    3,488,883

Canbiola,
Inc. and Subsidiary

Consolidated Statements of Cash Flows

Year Ended December 31, 

    
    2018
    2017

    Operating Activities: 
    
    

    Net loss 
    $(4,112,277) 
    $(2,139,719)

    Adjustments to reconcile net loss to net cash used in operating activities: 
    
    

    Stock-based compensation, net of prepaid stock- based consulting fees 
     2,779,300  
     231,590 

    Loss on Forgiveness of receivable from Pure Health Products 
     85,827  
    –

    Loss on stock issuance 
     649,259  
     191,553 

    Loss on debt conversion 
     1,299,369  
     32,383 

    Debt issuance expense 
     14,000  
    –

    Impairment of intangible assets 
    –
     21,507 

    Expense from derivative liability 
     (1,591,137) 
     915,700 

    Depreciation of property and equipment 
     5,473  
     3,227 

    Amortization of intangible assets 
    –
     3,972 

    Amortization of debt discounts 
     176,497  
     250,188 

    Bad debt expense 
    –
     16,840 

    Changes in operating assets and liabilities: 
    
    

    Comptes débiteurs
     (33,097) 
     (9,173)

    Inventaire
     2,382  
     (9,834)

    Security deposit 
     (34,939) 
    –

    Prepaid expenses 
    –
    2500

    Comptes à payer
     (115,235) 
     88,566 

    Accrued officers compensation 
     85,900  
     91,803 

    Other accrued expenses payable 
     35,109  
     22,606 

    Net cash used in operating activities 
     (753,569) 
     (286,291)

    Investing Activities: 
    
    

    Cash received from acquisition of Pure Health Products, LLC 
    404
    –

    Note receivable – current 
    –
     (75,000)

    Fixed assets additions 
     (46,384) 
    –

    Net cash used in investing activities 
     (45,980) 
     (75,000)

    Financing Activities: 
    
    

    Repayments of notes and loans payable 
     (123,231) 
    –

    Proceeds received from notes and loans payable 
    155 000
     182,750 

    Proceeds from sale of common stock 
     850,000  
    –

    Proceeds from sale of Series B preferred stock 
     723,875  
     150,000 

    Net cash provided by financing activities 
     1,605,644  
     332,750 

    Increase (decrease) in cash and cash equivalents 
     806,095  
     (28,541)

    Cash and cash equivalents, beginning of period 
     1,652  
     30,193 

    Cash and cash equivalents, end of period 
    $807,747  
    $1,652 

    SUPPLEMENTAL CASH FLOW INFORMATION: 
    
    

    Income taxes paid 
    $-  
    $- 

    Intérêts payés
    $-  
    $- 

    NON-CASH INVESTING AND FINANCING ACTIVITIES: 
    
    

    Issuance of common stock in satisfaction of debt 
    262 000 $
    115 000 $

    Issuance of common stock in satisfaction Of officers compensation 
    $282,200  
    $127,803 

    Issuance of common stock in acquisition of PureHealth, LLC 
    $178,997  
    $- 

    Cancellation of note receivable and accrued interest in exchange for service 
    $19,611  
    $- 

    Cancellation of note receivable and accrued interest in acquisition of PureHealth, LLC 
    $85,827,25  
    $- 

    Issuance of common stock in satisfaction of accrued interest 
    $43,043  
    $11,168

Voir
notes to consolidated financial statements.

Canbiola,
Inc. and Subsidiary

Remarques
to Consolidated Financial Statements

Années
Ended December 31, 2018 and 2017

REMARQUE
1 – Organization and Description of Business

Canbiola,
Inc. was originally incorporated as WrapMail, Inc. (“WRAP”) in Florida on October 11, 2005. Effective January 5, 2015,
WRAP acquired 100% ownership of Prosperity Systems, Inc. (“Prosperity”), a New York corporation incorporated on April
2, 2008. The Company is in the process of dissolving Prosperity. The Company acquired 100% of the membership interests in Pure
Health Products, LLC, a New York limited liability company (“PHP” or “Pure Health Products”) effective
December 28, 2018. The Company formed Duramed, Inc., a Nevada corporation (“Duramed”) in November 2018, to facilitate
the manufacture and sale of durable medical equipment incorporating CBD

Efficace
December 27, 2010, WRAP effected a 10 for 1 forward stock split of its common stock. Effective June 4, 2013, WRAP effected a 1
for 10 reverse stock split of its common stock. The accompanying consolidated financial statements retroactively reflect these
stock splits.

Sur
May 15, 2017, WRAP changed its name to Canbiola, Inc. (the “Company” or “CANB” or “Canbiola”).

Canbiola
specializes in the production and sale of a variety of hemp derived Cannabidiol (“CBD”) products such as oils, creams,
moisturizers, isolate, gel caps, concentrate and water. Canbiola is developing its own line of proprietary products as well as
seeking synergistic value through acquisitions in the Hemp Industry. Canbiola aims to be the premier provider of the highest quality
hemp CBD products on the market through sourcing the very best raw material and developing a variety of products we believe will
improve people’s lives in a variety of areas.

le
Company also operates document management and email marketing platforms. The Company used to operate its document and information
platform from its wholly owned subsidiary, Prosperity Systems, Inc; however, after the acquisition of Prosperity, the Company
transferred Prosperity’s operations to the Company directly.

Pour
the periods presented, the assets, liabilities, revenues, and expenses are those of CANB. Prosperity and Duramed had no activity
for the periods presented. Financial information for PHP from December 28, 2018 to December 31, 2018 has been consolidated with
the Company’s financials.

REMARQUE
2 – Going Concern Uncertainty

le
consolidated financial statements have been prepared on a “going concern” basis, which contemplates the realization
of assets and liquidation of liabilities in a normal course of business. As of December 31, 2018, the Company had cash and cash
equivalents of $807,747 and a working capital of $939,582. For the years ended December 31, 2018 and 2017, the Company had net
losses of $4,112,277 and $2,139,719, respectively. These factors raise substantial doubt as to the Company’s ability to
continue as a going concern. The Company plans to improve its financial condition by raising capital through sales of shares of
its common stock. Also, the Company plans to expand its operation of CBD products to increase its profitability. The consolidated
financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going
concern.

REMARQUE
3 – Summary of Significant Accounting Policies

(une)
Principles of Consolidation

le
consolidated financial statements include the accounts of CANB and its wholly owned subsidiaries, Pure Health products (from its
acquisition date of December 28, 2018), Duramed, and Prosperity from the date of its acquisition on January 5, 2015. All intercompany
balances and transactions have been eliminated in consolidation.

(b)
Use of Estimates

le
preparation of financial statements in conformity with accounting principles generally accepted in the United States requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting
periods. Actual results could differ from those estimates.

(c)
Fair Value of Financial Instruments

le
Company’s financial instruments consist of cash and cash equivalents, accounts receivable, notes receivable, notes and loans
payable, accounts payable, and accrued expenses payable. Except for the noncurrent note receivable, the fair value of these financial
instruments approximate their carrying amounts reported in the balance sheets due to the short term maturity of these instruments.
Based on comparable instruments with similar terms, the fair value of the noncurrent note receivable approximates its carrying
valeur.

Pursuant
to ASC 820, Fair Value Measurements and Disclosures, an entity is required to maximize the use of observable inputs and minimize
the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent,
objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the
fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes
the inputs into three levels that may be used to measure fair value:

Niveau
1 – applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

Niveau
2 – applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or
liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities
in markets with insufficient volume or infrequent transactions (less active markets); or model derived valuations in which significant
inputs are observable or can be derived principally from, or corroborated by, observable market data.

Niveau
3 – applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant
to the measurement of the fair value of the assets or liabilities.

(ré)
Trésorerie et équivalents de trésorerie

le
Company considers all liquid investments purchased with a maturity of three months or less to be cash equivalents.

e)
Inventaire

Tout
inventories are finished goods and stated at the lower of cost or net realizable value. Cost is principally determined using the
first-in, first-out (FIFO) method.

(F)
Property and Equipment, Net

Propriété
and equipment, net, is stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method
over the estimated useful lives of the respective assets. Maintenance and repairs are charged to operations as incurred.

(g)
Intangible Assets, Net

Intangible
assets, net, are stated at cost less accumulated amortization. Amortization is calculated using the straight-line method over
the estimated economic lives of the respective assets.

(h)
Goodwill and Intangible Assets with Indefinite Lives

le
Company does not amortize goodwill and intangible assets with indefinite useful lives, but instead tests for impairment at least
annually. When conducting the annual impairment test for goodwill, the Company compares the estimated fair value of a reporting
unit containing goodwill to its carrying value. If the estimated fair value of the reporting unit is determined to be less than
its carrying value, goodwill is reduced, and an impairment loss is recorded.

(je)
Long-lived Assets

le
Company reviews long-lived assets held and used, intangible assets with finite useful lives and assets held for sale for impairment
whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If an evaluation
of recoverability is required, the estimated undiscounted future cash flows associated with the asset is compared to the asset’s
carrying amount to determine if a write-down is required. If the undiscounted cash flows are less than the carrying amount, an
impairment loss is recorded to the extent that the carrying amount exceeds the fair value.

(j)
Revenue Recognition

le
Company recognizes revenue in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards
Codification (“ASC”) 606, Revenue from Contracts with Customers, which requires that five basic steps be followed
to recognize revenue: (1) a legally enforceable contract that meets criterial standards as to composition and substance is identified;
(2) performance obligations relating to provision of goods or services to the customer are identified; (3) the transaction price,
with consideration given to any variable, noncash, or other relevant consideration, is determined; (4) the transaction price is
allocated to the performance obligations; and (5) revenue is recognized when control of goods or services is transferred to the
customer with consideration given, whether that control happens over time or not. Determination of criteria (3) and (4) are based
on our management’s judgments regarding the fixed nature of the selling prices of the products and services delivered and
the collectability of those amounts.

Privé
Label Customers, Global CBD, LLC and TZ Wholesale, are wholesale distributors of the Company’s product, under their own
wholesale private label brand. The products are made to Company specifications, and shipped directly to the wholesaler. The pricing
is predicated upon a volume discount negotiated at the time of the placement of the orders. Product is produced and labeled in
the Washington manufacturing facility and shipped directly to the Private Label customer who re-distributes to their retail and
other customers. The products are fully paid when shipped. For 2018, Global CBD, LLC revenue of $44,602 represents approximately
9% and TZ Wholesale revenue of $17,172 represents approximately 3.5% of total Company revenues for the year ended December 31,
2018.

Revenu
from product sales is recognized when an order has been obtained, the price is fixed and determinable, the product is shipped,
title has transferred, and collectability is reasonably assured.

Aditionellement,
the Company also generates revenue from email marketing and cloud service provided to several existing customers. The service
revenue is recognized over agreed periods of services delivered to customers, provided there are no uncertainties regarding customer
acceptance, persuasive evidence of an arrangement exists; the sales price is fixed or determinable; and collectability is deemed
probable.

(k)
Cost of Product Sales

le
cost of product sale is the total cost incurred to obtain a sale and the cost of the goods sold, and the Company’s policy
is to recognize it in the same manner as, and in conjunction with, revenue recognition. Cost of product sale primarily consisted
of the costs directly attributable to revenue recognized and includes expenses related to the production, packaging and labeling
of our CBD products.

(l)
Stock-Based Compensation

Stock-based
compensation is accounted for at fair value in accordance with Accounting Standards Codification (“ASC”) Topic 718,
“Compensation – Stock Compensation” (“ASC718”) and ASC 505-50, “Equity – Based Payments
to Non-Employees.”

Dans
addition to requiring supplemental disclosures, ASC 718 addresses the accounting for share-based payment transactions in which
a company receives goods or services in exchange for (a) equity instruments of the company or (b) liabilities that are based on
the fair value of the company’s equity instruments or that may be settled by the issuance of such equity instruments. ASC
718 focuses primarily on accounting for transactions in which a company obtains employee services in share-based payment transactions.

Dans
accordance with ASC 505-50, the Company determines the fair value of the stock based payment as either the fair value of the consideration
received or the fair value of the equity instruments issued, whichever is more reliably measurable. If the fair value of the equity
instruments issued is used, it is measured using the stock price and other measurement assumptions as of the earlier of either
(1) the date at which a commitment for performance by the counterparty to earn the equity instrument is reached, or (2) the date
at which the counterparty’s performance is complete.

Options
and warrants

le
fair value of stock options and warrants is estimated on the measurement date using the Black-Scholes model with the following
assumptions, which are determined at the beginning of each year and utilized in all calculations for that year:

Risk-Free
    Interest Rate.

    
    nous
    utilized the U.S. Treasury yield curve in effect at the time of grant with a term consistent with the expected term of our
    awards.

    
    Expected
    Volatility.

    
    nous
    calculate the expected volatility based on a volatility index of peer companies as we did not have sufficient historical market
    information to estimate the volatility of our own stock.

    
    Dividend
    Yield.

    
    nous
    have not declared a dividend on its common stock since its inception and have no intentions of declaring a dividend in the
    foreseeable future and therefore used a dividend yield of zero.

    
    Expected
    Term.

    
    le
    expected term of options granted represents the period of time that options are expected to be outstanding. We estimated
    the expected term of stock options by using the simplified method. For warrants, the expected term represents the actual term
    of the warrant.

    
    Forfeitures.
    

    
    Estimates
    of option forfeitures are based on our experience. We will adjust our estimate of forfeitures over the requisite service period
    based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated
    forfeitures will be recognized through a cumulative catch-up adjustment in the period of change and will also impact the amount
    of compensation expense to be recognized in future periods.

(m)
La publicité

La publicité
costs are expensed as incurred and amounted to $84,316 and $28,322 for the year ended December 31, 2018 and 2017, respectively.

(n)
Recherche et développement

Recherche
and development costs are expensed as incurred. In fiscal year 2017 and 2018, the Company spent $37,000 and $75,000 in research
and development which was expenses as spent, respectively.

(o)
Impôts sur le revenu

le revenu
taxes are accounted for under the assets and liability method. Current income taxes are provided in accordance with the laws of
the respective taxing authorities. Deferred income taxes are provided for the estimated future tax consequences attributable to
differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases
and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates in effect
for the year in which those temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by
a valuation allowance when, in the opinion of management, it is not more likely than not that some portion or all of the deferred
tax assets will be realized.

le
Company has adopted the provisions required by the Income Taxes topic of the FASB Accounting Standards Codification. The Codification
Topic requires the recognition of potential liabilities as a result of management’s acceptance of potentially uncertain
positions for income tax treatment on a “more-likely-than-not” probability of an assessment upon examination by a
respective taxing authority. The Company believes that it has not taken any uncertain tax positions and thus has not recorded
any liability.

(p)
Net Income (Loss) per Common Share

De base
net income (loss) per common share is computed on the basis of the weighted average number of common shares outstanding during
the period.

Dilué
net income (loss) per common share is computed on the basis of the weighted average number of common shares and dilutive securities
(such as stock options and convertible securities) outstanding. Dilutive securities having an anti-dilutive effect on diluted
net income (loss) per share are excluded from the calculation. For the periods presented, the diluted net loss per share calculation
excluded the effect of Series B preferred stocks and stock options outstanding (see Notes 7, 8 and 10).

(q)
Recent Accounting Pronouncements

Dans
May 2014, the FASB issued ASU 2014-09 “Revenue from Contracts with Customers” (Topic 606) which establishes revenue
recognition standards. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2017. The impact of
ASU 2014-09 on the Company’s financial statements has not been significant.

Dans
2016, the FASB issued ASU 2016-2 (Topic 842) which establishes a new lease accounting model for lessees. Under the new guidance,
lessees will be required to recognize right of use assets and liabilities for most leases having terms of 12 months or more. ASU
2016-2 is effective for fiscal years beginning after December 15, 2018.

le
impact on the Company’s financial statements has not yet been determined.

(r)
Reclassifications

Certain
amounts in the prior year consolidated financial statements have been reclassified to conform to the current year presentation.
These reclassification adjustments had no effect on the Company’s previously reported net income.

REMARQUE
4 – Acquisition of Pure Health Products, LLC

Efficace
December 28, 2018, CANB acquired 100% ownership of Pure Health Products, LLC (“Pure Health”) in exchange for the cancellation
of CANB’s $75,000 note receivable from Pure Health and $10,827 accrued interest thereon and issuance of 3,096,827 newly
issued shares of CANB common stock (valued at the $0.0578 closing trading price on December 28, 2018 or $178,997, see Note 11).
The acquisition has been accounted for in the accompanying consolidated financial statements as a purchase transaction. En conséquence,
the financial position and results of operations of Pure Health prior to the date of the acquisition have been excluded from the
accompanying consolidated financial statements.

le
estimated fair values of the identifiable net assets of Pure Health at December 28, 2018 (effective date of acquisition), after
cancellation of the $75,000 note payable to CANB and $10,827 accrued interest thereon, consisted of:

Trésorerie et équivalents de trésorerie
    404 $

    Accounts receivable from CANB 
     16,676 

    Inventaire
     79,652 

    Property and equipment, net 
     7,559 

    Security deposit 
     2,100

Total des actifs

106,391 

    Accounts payable, including $34,419 due to CANB 
     49,825 

    Total liabilities 
     49,825 

    Identifiable net assets 
    $56,566

Bonne volonté
of $55,849 (excess of the $112,415 fair value of the 3,096,827 shares of CANB common stock issued to Pure Health’s stockholders
over the $56,566 identifiable net assets of Pure Health at December 28, 2018 after reflecting the $85,827 cancellation of the
$75,000 note payable and $10,827 accrued interest) was recorded from the acquisition.

le
following pro forma information summarizes the results of operations for the periods indicated as if the acquisition occurred
at December 31, 2016. The pro forma information is not necessarily indicative of the results that would have been reported had
the transaction actually occurred on December 31, 2016, nor is it intended to project results of operations for any future period.

Year Ended 

    
    Le 31 décembre,

    
    2018
    2017

    Product sales 
    $651,978  
    $90,634 

    Cost of product sales 
     224,894  
     62,958 

    Gross profit on product sales 
     427,084  
     27,676 

    Service revenue 
     16,625  
     43,716 

    Total gross profit 
     443,709  
     71,392 

    Dépenses d'exploitation
     4,674,321  
     812,365 

    Loss from operations 
     (4,203,613) 
     (740,973)

    Other income (loss) – net 
     (2,671,581) 
     (1,428,783)

    Net loss 
    $(6,875,194) 
    $(2,169,756)

    Net loss per common share- basic and diluted 
    $(0.02) 
    $(0.01)

    Weighted average common shares outstanding – 
    
    

    De base
     276,026,704  
     165,230,550 

    Dilué
     423,881,781  
     256,295,851

REMARQUE
5 – Inventories

Inventories consist of:

Le 31 décembre,
2018
    Le 31 décembre,
2017

    Raw materials 
    $79,652  
    $- 

    Finished goods 
     7,452  
     9,834 

    Total
    $87,104  
    $9,834

REMARQUE
6 – Notes Receivable

Remarques
    receivable consist of:

Le 31 décembre,
2018
    Le 31 décembre,
2017

    Secured Promissory note dated October 17, 2017 due from Pure Health Products, LLC (“PHP”), interest at 12% per annum, due October 17, 2018, secured by assets of PHP. Cancelled in acquisition of Pure Health Products, LLC 
    $-  
    75 000 $

    Note receivable dated November 30, 2015 from Stock Market Manager, Inc, interest at 3% per annum due November 30, 2020 
     19,389  
     39,000 

    Total
     19,389  
     114,000 

    Current portion of notes receivable 
    –
     (75,000)

    Noncurrent portion of notes receivable 
    $19,389  
    $39,000

Pursuant
to an option Agreement dated November 10, 2017, the Company has an option expiring November 10, 2027 to purchase certain specified
assets of Pure Health for $75,000, payable via cancellation of Pure Health’s obligations under the Secured Promissory Note
or in cash or cash equivalent.

Stock
Market Manager, Inc is affiliated with Carl Dilley, a Company director. In 2018, the Company received services from Stock Market
Manager valued at $19,611 in exchange for the cancellation of $19,611 in note receivables.

REMARQUE
7 – Property and Equipment, Net

Propriété
and Equipment, net, consist of:

Le 31 décembre,
    Le 31 décembre,

    
    2018
    2017

    Furniture & Fixtures 
    $19,018  
    $19,018 

    Office Equipment 
     20,992  
     12,378 

    Manufacturing Equipment 
     46,384  
    –

    Total
     86,394  
     31,396 

    Accumulated amortization 
     (26,775) 
     (20,248)

    Net 
    $59,619  
    $11,148

REMARQUE
8 – Intangible Assets, Net

Intangible
assets, net, consist of:

Le 31 décembre,
    Le 31 décembre,

    
    2018
    2017

    Video conferencing software acquired by Prosperity in December 2009 
    $30,000  
    $30,000 

    Enterprise and audit software acquired by Prosperity in April 2008 
    20 000
    20 000

    Patent costs incurred by WRAP 
     6,880  
     6,880 

    Autre
     3,548  
     3,548 

    Total
     60,428  
     60,428 

    Accumulated amortization and Impairment 
     (60,428) 
     (60,428)

    Net 
    0 $
    0 $

le
above intangible assets relate to the document management and email marketing divisions. At December 31, 2017, we do not expect
any future positive cash flow from these divisions. Accordingly, we have recorded an impairment expense of $21,509 at December
31, 2017 and reduced the net carrying value of these intangible assets to $0.

REMARQUE
9 – Notes and Loans Payable

Notes and loans payable consist of: 
    
    

    
    Le 31 décembre,
2018
    Le 31 décembre,
2017

    Convertible notes payable to lender dated from March 15, 2016 (as amended June 2, 2016) to November 15, 2017, interest at rates ranging from 12% to 14.99% per annum, due from April 6, 2017 to May 15, 2018, partially converted at March 22, 2017 and the remaining notes convertible into Common Stock at a Conversion Price equal to the lesser of (i) $0.01 per share or (ii) 50% of the lowest Closing Bid Price of the Common Stock for the 30 Trading Days preceding the Conversion Date – net of unamortized debt discount of $0 and $1,815, respectively-fully converted on August 31, 2018 
    –
     36,685 

    Convertible notes payable to lender dated February 1, 2016 (as amended
December 21, 2016) and December 21, 2016, interest at 12% per
annum, due February 1, 2017 and May 20, 2017, convertible into
Common Stock at a Conversion Price equal to the lesser of (i) $0.01 per
share or (ii) 50% of the lowest Closing Bid Price of the Common Stock
for the 30 Trading Days preceding the Conversion Date – net of
unamortized debt discount of $0 and $0, respectively. The note date dated
February 1, 2016 was fully converted at June 11, 2018 while note dated December 21, 2016 was fully converted at September 7, 2018 
    –
     65,000 

    Convertible notes payable to Pasquale and Rosemary Ferro dated from
May 2, 2017 to August 10, 2018, interest at 12% per annum, due at June
30, 2020 (as amended August 13, 2018), convertible into Common Stock
at a Conversion Price equal to the lesser of (i) $0.01 per share or (ii) 50%
of the lowest Closing Bid Price of the Common Stock for the 30 Trading
Days preceding the Conversion Date – net of unamortized debt discount
of $25,009 and $19,613, respectively. The notes were fully converted at
August 9, 2018 and December 21, 2018. 
    –
     73,887 

    Convertible note payable to lender dated August 8, 2017 interest at 12% per annum, due August 8, 2018, convertible into Common Stock at a
Conversion Price equal to the lesser of (i) $0.01 per share or (ii) 50% of
the lowest Closing Bid Price of the Common Stock for the 30 Trading
Days preceding the Conversion Date – net of unamortized debt discount
of $0 and $15,068, respectively. The notes were fully converted at
August 31, 2018. 
    –
     9,932 

    Convertible note payable to lender dated June 6, 2018, interest at 12% per
annum, due March 6, 2019, convertible into Common Stock at a
Conversion Price equal to the lesser of 55% of the lowest Closing Bid
. Price of the Common Stock for the 25 Trading Days preceding the
(i) Inception date or (ii) the Conversion Date – net of unamortized debt
discount of $57,509 and $0, respectively. The note was fully paid off at
October 19, 2018. 
    –
    –

    Note payable to brother of Marco Alfonsi, Chief Executive Officer of the Company, interest at 10% per annum, due August 22, 2016 (now past due) 
    5 000
    5 000

    Note payable to Carl Dilley, a director of the Company, interest at 12.99% per annum, due February 1, 2021 
     10,899  
    –

    Loan payable to Mckenzie Webster Limited (“MWL”), an entity controlled by the former Chairman of the Board of Directors of the Company, non-interest bearing, due on demand 
    3000
    3000

    Total
    $18,899  
    $193,504

le
derivative liability of the convertible notes payable consists of:

décembre
    31, 2018  
    décembre
    31, 2017 

    
    Face
    Valeur
    Derivative
    Responsabilité
    Face
    Valeur
    Derivative
    Responsabilité

    Convertible
    notes payable to lender dated from March 15, 2016 (as amended June 2, 2016) to November 15, 2017, due from April
    6, 2017 to May 15, 2018. Fully converted on August 31, 2018 
    $-  
    $-  
     38,500  
     248,597 

    Convertible
    notes payable to lender dated February 1, 2016 (as amended December 21, 2016) and December 21, 2016, due February
    1, 2017 and May 20, 2017. The notes were fully converted at June 11, 2018 and September 7, 2018 
    –
    –
     65,000  
     418,889 

    Convertible
    notes payable to Pasquale and Rosemary Ferro dated from May 25, 2017 to January 8, 2018, due at June 30, 2020
    (as amended August 13, 2018), 
    –
    –
     93,500  
     611,886 

    Convertible
    notes payable to lender dated June 6, 2018, due March 6, 2019. Fully paid off at October 19, 2018. 
    –
    –
    –
    –

    Convertible
    notes payable to lender dated August 8, 2017, due August 8, 2018. Fully converted at August 31, 2018 
    –
    –
    25 000
     171,765 

    Totaux
    $-  
    $-  
    $222,000  
    $1,451,137

le
above convertible notes outstanding at December 31, 2017 contained a variable conversion feature based on the future trading price
of the Company common stock. Therefore, the number of shares of common stock issuable upon conversion of the notes was indeterminate.
Accordingly, we recorded the fair value of the embedded conversion features as a derivative liability at the respective issuance
dates (or amendment dates) of the notes ($445,112 total for the year ended December 31, 2017) and charged the applicable amounts
to debt discounts of ($182,750 total for the year ended December 31, 2017) and the remainder to other expense ($262,362 total
for the year ended December 31, 2017). The increase (decrease) in the fair value of the derivative liability from the respective
issuance dates (or amendment dates) of the notes to the measurement date ($926,819 total increase for the year ended December
31, 2017) are charged (credited) to other expense (income). The fair value of the derivative liability of the notes is measured
at the respective issuance dates and quarterly thereafter using the Black Scholes option pricing model. Assumptions used for the
calculations of the derivative liability of the notes at December 31, 2017 include (1) stock price of $0.0335 per share, (2) exercise
price of $0.0045 per share, (3) terms ranging from 0 days to 220 days, (4) expected volatility of 287% and (5) risk free interest
rates ranging from 0.00% to 1.58%.

Dans
2018, all convertible notes containing embedded conversion features were satisfied and the Company recognized income from derivative
liability of $1,591,137

REMARQUE
10 – Preferred Stock

Each
share of Series A Preferred Stock is convertible into 10,000,000 shares of CANB common stock and is entitled to 20,000,000 votes.

Each
share of Series B Preferred Stock has the first preference to dividends, distributions and payments upon liquidation, dissolution
and winding-up of the Company, and is entitled to an accrued cumulative but not compounding dividend at the rate of 5% per annum
whether or not declared. After six months of the issuance date, such share and any accrued but unpaid dividends can be converted
into common stock at the conversion price which is the lower of (i) $0.0101; or (ii) the lower of the dollar volume weighted average
price of CANB common stock on the trading day prior to the conversion day or the dollar volume weighted average price of CANB
common stock on the conversion day. The shares of Series B Preferred Stock have no voting rights.

le
Company issued a total of 10 shares of CANB Series A Preferred Stock (5 shares to Mckenzie Webster Limited and 5 shares to Marco
Alfonsi) in exchange for the retirement of a total of 100,000,000 shares of CANB common stock (50,000,000 shares from Mckenzie
Webster Limited and 50,000,000 shares from Marco Alfonsi).

Sur
October 4, 2017, the Company issued 3 shares of CANB Series A Preferred Stock to Alfonsi: 2 shares were the consideration for
Alfonsi’s cancellation of accrued salaries payable of $127,803 owed to Alfonsi and 1 share (valued at $63,902) was issued
pursuant to the new employment agreement with Alfonsi.

Sur
November 30, 2017, MWL converted its 5 shares of CANB Series A Preferred Stock to 50,000,000 shares of CANB common stock.

Sur
December 5, 2017, the Company issued 157,985 shares of CANB Series B Preferred Stock to RedDiamond Partners LLC (“RedDiamond”)
pursuant to a Securities Purchase Agreement (the “SPA”) dated October 13, 2017, in exchange for proceeds of $150,000,
or $0.95 per CANB Series B Preferred share.

Sur
January 22, 2018, the Company issued 87,368 shares of CANB Series B Preferred Stock to RedDiamond Partners LLC (“RedDiamond”)
pursuant to an amended Securities Purchase Agreement dated January 9, 2018, in exchange for proceeds of $83,000, or $0.95 per
CANB Series B Preferred share.

Sur
February 12, 2018, the Company issued 1 share of CANB Series A Preferred Stock to David Posel pursuant to a service agreement.
The fair value of the issuance is $257,370 and will be amortized over the vesting period of four years.

Sur
February 16, 2018, the Company issued 3 shares of CANB Series A Preferred Stock to Andrew Holtmeyer pursuant to a service agreement.
The fair value of the issuance is $703,800 and will be amortized over the vesting period of one year.

Sur
February 16, 2018, the Company issued 87,368 shares of CANB Series B Preferred Stock to RedDiamond Partners LLC (“RedDiamond”)
pursuant to an amended Securities Purchase Agreement dated January 9, 2018, in exchange for proceeds of $83,000, or $0.95 per
CANB Series B Preferred share.

Sur
March 20, 2018, the Company issued 87,368 shares of CANB Series B Preferred Stock to RedDiamond Partners LLC (“RedDiamond”)
pursuant to an amended Securities Purchase Agreement dated January 9, 2018, in exchange for proceeds of $83,000, or $0.95 per
CANB Series B Preferred share.

Sur
April 13, 2018, April 25, 2018, May 3, 2018, June 19, 2018 and June 25, 2018, RedDiamond Partners converted its 10,000 shares,
10,000 shares, 10,000 shares, 15,000 shares and 10,000 shares of CANB Series B Preferred Stock to 1,287,129 shares, 1,287,129
shares, 1,287,129 shares, 3,545,455 shares, and 2,363,636 shares of CANB common stock, respectively.

Sur
May 14, 2018, the Company issued 1 share of CANB Series A Preferred Stock to a consultant pursuant to a Consulting Agreement dated
May 11, 2018. The $105,000 fair value of the issuance was partially charged to consulting fees in the three months ended September
30, 2018.

De
July 24, 2018 to September 26, 2018, RedDiamond Partners converted aggregately 263,263 shares of CANB Series B Preferred Stock
to 53,839,743 shares of CANB common stock.

Sur
August 28, 2018, September 14, 2018 and September 19, 2018, the Company issued 36,842 shares, 105,263 shares, and 105,263 shares
of CANB Series B Preferred Stock, respectively, to RedDiamond Partners LLC (“RedDiamond”) pursuant to an amended Securities
Purchase Agreement dated January 9, 2018, in exchange for proceeds of $35,000, $100,000 and $100,000, respectively, or $0.95 per
CANB Series B Preferred share.

De
October 2, 2018 to November 7, 2018, RedDiamond Partners converted aggregately 101,736 shares of CANB Series B Preferred Stock
to 13,094,733 shares of CANB common stock.

Sur
October 23, 2018 and November 14, 2018, the Company issued 200,000 shares and 52,500 shares of CANB Series B Preferred Stock,
respectively, to RedDiamond Partners LLC (“RedDiamond”) in exchange for proceeds of $190,000 and $49,875, respectively,
or $0.95 per CANB Series B Preferred share.

Sur
December 28,2018, Marco Alfonsi converted 3 shares of CANB Series A Preferred Stock to 30,000,000 shares of CANB common stock.

Sur
December 29, the Company issued 8 shares of CANB Series A Preferred Stock to three officers of the company (1 share to Stanley
L. Teeple, 5 shares to Pasquale Ferro and 2 shares to Andrew Holtmeyer), pursuant to the employment agreements with them. le
fair value of the issuance totaled at $3,375,520 and will be amortized over the vesting period of four years.

REMARQUE
11 – Common Stock

Sur
February 2, 2017, the Company issued 200,000 shares of CANB common stock to a financial consultant for services rendered. le
$11,000 fair value of the 200,000 shares of CANB common stock was charged to consulting fees in the three months ended March 31,
2017

Sur
February 13, 2017, the Company issued 1,685,900 shares of CANB common stock to the brother of the Chief Executive Officer of the
Company in satisfaction of notes payable of $15,000 and accrued interest payable of $1,859.

Sur
March 22, 2017, the Company issued 6,785,316 shares of CANB common stock to a lender in satisfaction of notes payable of $50,000
and accrued interest payable of $5,979.

Sur
April 17, 2017, the Company issued 5,000,000 shares of CANB common stock to a consultant for services rendered. The $125,000 fair
value of the 5,000,000 shares of CANB common stock was charged to consulting fees in the three months ended June 30, 2017.

Sur
June 21, 2017, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $5,975 fair value
of the 250,000 shares of CANB common stock was charged to consulting fees in the three months ended June 30, 2017.

Sur
June 28, 2017, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $5,000 fair value
of the 250,000 shares of CANB common stock was charged to consulting fees in the three months ended June 30, 2017.

Sur
August 25, 2017, the Company issued 7,142,857 shares of CANB common stock to a lender in satisfaction of notes payable of $50,000
and accrued interest payable of $3,331.

Sur
August 25, 2017, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $3,750 fair
value of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended September
30, 2017.

Sur
September 5, 2017, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $4,375 fair
value of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended September
30, 2017.

Sur
September 7, 2017, the Company issued 2,500,000 shares of CANB common stock to a consultant for services rendered. The $32,750
fair value of the 2,500,000 shares of CANB common stock was charged to consulting fees in the three months ended September 30,
2017. On July 12, 2018, the consultant agreed to return the 2,500,000 shares

à
the Company due to the lack of service after an arbitration was filed on May 11,2018.

Sur
September 11, 2017, the Company issued 250,000 and 250,000 shares of CANB common stock to two consultants for services rendered,
respectivement. The $3,350 fair value of each 250,000 shares of CANB common stock was partially charged to consulting fees in the
three months ended September 30, 2017.

Sur
September 25, 2017, the Company issued 2,500,000 shares of CANB common stock to a consultant for services rendered. The $2,525
fair value of the 2,500,000 shares of CANB common stock was partially charged to consulting fees in the three months ended September
30, 2017.

Sur
November 2, 2017, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $1,725 fair
value of the 250,000 shares of CANB common stock was charged to consulting fees in the three months ended December 31, 2017.

Sur
November 9, 2017, the Company issued 2,500,000 shares of CANB common stock to a consultant for services rendered. The $21,250
fair value of the 2,500,000 shares of CANB common stock was partially charged to consulting fees in the three months ended December
31, 2017.

Sur
November 30, 2017, the Company issued 50,000,000 shares of CANB common stock to Mckenzie Webster Limited in exchange for the retirement
of 5 shares of CANB Series A Preferred Stock.

Sur
December 5, 2017, the Company issued 250,000 and 250,000 shares of CANB common stock to two consultants for services rendered,
respectivement. The $3,000 fair value of each 250,000 shares of CANB common stock was partially charged to consulting fees in the
three months ended December 31, 2017.

Sur
December 7, 2017, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $4,500 fair
value of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended December 31,
2017

Sur
December 18, 2017, the Company issued 500,000 shares of CANB common stock to a consultant for services rendered. The $9,050 fair
value of the 500,000 shares of CANB common stock was partially charged to consulting fees in the three months ended December 31,
2017

Sur
December 25, 2017, the Company issued 250,000 and 250,000 shares of CANB common stock to two consultants for services rendered,
respectivement. The $7,250 fair value of each 250,000 shares of CANB common stock was partially charged to consulting fees in the
three months ended December 31, 2017.

Sur
February 7, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $9,825 fair
value of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended March 31,
2018.

Sur
February 9, 2018, the Company issued 3,000,000 and 3,000,000 shares of CANB common stock to its two directors for services rendered,
respectivement. The $101,400 fair value of each 3,000,000 shares of CANB common stock was charged to directors fees in the three
months ended March 31, 2018. The shares issued to one of the directors were converted to options at June 11, 2018 (see Note 10).

Sur
February 13, 2018, the Company issued 150,000 shares of CANB common stock to a consultant for services rendered. The $5,085 fair
value of the 150,000 shares of CANB common stock was partially charged to consulting fees in the three months ended March 31,
2018.

Sur
February 14, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $8,500 fair
value of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended March 31,
2018.

Sur
February 19, 2018, the Company issued 150,000 shares of CANB common stock to a consultant for services rendered. The $5,280 fair
value of the 150,000 shares of CANB common stock was partially charged to consulting fees in the three months ended March 31,
2018.

Sur
February 26, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $11,375 fair
value of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended March 31,
2018.

Sur
March 1, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $10,900 fair
value of the 250,000 shares of CANB common stock was charged to consulting fees in the three months ended March 31, 2018.

Sur
March 20, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $6,500 fair
value of the 250,000 shares of CANB common stock was charged to consulting fees in the three months ended March 31, 2018.

Sur
April 13, 2018, April 25, 2018, May 3, 2018, June 19, 2018 and June 25, 2018, the Company issued 1,287,129 shares, 1,287,129 shares,
1,287,129 shares, 3,545,455 shares, and 2,363,636 shares of CANB common stock to RedDiamond in exchange for the retirement of
10,000 shares, 10,000 shares, 10,000 shares, 15,000 shares and 10,000 shares of CANB Series B Preferred Stock, respectively.

Sur
May 9, 2018, the Company issued 125,000 shares of CANB common stock to a consultant for services rendered. The $1,812 fair value
of the 125,000 shares of CANB common stock was partially charged to consulting fees in the three months ended June 30, 2018.

Sur
May 29, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $5,000 fair value
of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended June 30, 2018.

Sur
May 31, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $4,600 fair value
of the 250,000 shares of CANB common stock was charged to consulting fees in the three months ended June 30, 2018.

Sur
June 4, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $5,750 fair value
of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended June 30, 2018.

Sur
June 11, 2018, the Company agreed to issue 2,749,429 shares of CANB common stock to a lender in satisfaction of notes payable
of $15,000 and accrued interest payable of $4,246. The shares was issued at August 24, 2018.

Sur
June 18, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $6,250 fair value
of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended June 30, 2018.

Sur
June 22, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $8,250 fair value
of the 250,000 shares of CANB common stock was charged to consulting fees in the three months ended June 30, 2018.

De
July 24, 2018 to September 26, 2018, the Company issued aggregately 53,839,743 shares of CANB common stock to RedDiamond in exchange
for the retirement of 263,263 shares of CANB Series B Preferred Stock.

Sur
July 31, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $3,225 fair value
of the 250,000 shares of CANB common stock was charged to consulting fees in the three months ended September 30, 2018.

Sur
August 9, 2018, Company received a conversion notice from a lender. As a result, 9,544,292 shares of CANB common stock was issued
to the lender in satisfaction of notes payable of $50,000 and accrued interest payable of $7,266 at August 21, 2018.

Sur
August 28, 2018, the Company issued 2,000,000 shares of CANB common stock to a consultant for services rendered. The $159,600
fair value of the 2,000,000 shares of CANB common stock was partially charged to consulting fees in the three months ended September
30, 2018.

Sur
September 6, 2018, the Company issued 300,000 shares of CANB common stock to a consultant for services rendered. The $16,500 fair
value of the 300,000 shares of CANB common stock was partially charged to consulting fees in the three months ended September
30, 2018.

Sur
September 6, 2018, the Company issued 500,000 shares of CANB common stock to a consultant for services rendered. The $27,500 fair
value of the 500,000 shares of CANB common stock was charged to consulting fees in the three months ended September 30, 2018.

Sur
September 6, 2018, the Company issued 8,430,331 shares of CANB common stock to a lender in satisfaction of notes
payable of $38,500 and accrued interest payable of $7,867.

Sur
September 7, 2018, the Company issued 5,121,694 shares of CANB common stock to a lender in satisfaction of notes payable of
$25,000 and accrued interest payable of $3,169.

Sur
September 7, 2018, the Company issued 10,045,667 shares of CANB common stock to a lender in satisfaction of notes payable of
$50,000 and accrued interest payable of $10,274.

Sur
September 8, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $11,500 fair
value of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended September
30, 2018.

Sur
September 10, 2018, the Company issued 500,000 shares of CANB common stock to a consultant for services rendered. The $19,950
fair value of the 500,000 shares of CANB common stock was partially charged to consulting fees in the three months ended September
30, 2018.

Sur
September 17, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $10,750
fair value of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended September
30, 2018.

Sur
September 18, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $13,725
fair value of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended September
30, 2018.

Sur
September 20, 2018, the Company issued 7,407,407 shares of CANB common stock to an investor pursuant to a Stock Purchase Agreement
dated September 17, 2018, in exchange for proceeds of $200,000, or $0.027 per CANB common share.

Sur
September 21, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $14,500
fair value of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended September
30, 2018.

Sur
September 25, 2018, the Company issued 2,000,000 shares of CANB common stock to a consultant for services rendered. The $97,400
fair value of the 2,000,000 shares of CANB common stock was partially charged to consulting fees in the three months ended September
30, 2018.

De
October 2, 2018 to November 7, 2018, the Company issued aggregately 13,094,733 shares of CANB common stock to RedDiamond in exchange
for the retirement of 101,736 shares of CANB Series B Preferred Stock.

De
November 5, 2018 to December 28, 2018, the Company issued aggregately 2,125,000 shares of CANB common stock to multiple consultants
for services rendered. The $80,665 fair value of the 2,125,000 shares of CANB common stock was partially charged to consulting
fees in the three months ended December 30, 2018.

De
December 3, 2018 to December 28, 2018, the Company issued aggregately 1,500,000 shares of CANB common stock to three board members
for services rendered. The $62,342 fair value of the 1,500,000 shares of CANB common stock was charged to director fees in the
three months ended December 30, 2018.

De
December 3, 2018 to December 28, 2018, the Company issued aggregately 22,413,794 shares of CANB common stock to multiple investors
pursuant to relative Stock Purchase Agreements dated on various dates, in exchange for total proceeds of $650,000.

Sur
December 11, 2018, the Company issued 891,089 shares of CANB common stock to RedDiamond in satisfaction of dividend payable of
$9.000.

Sur
December 19, 2018, the Company issued 891,089 shares of CANB common stock to Auctus, LLC pursuant to a cashless exercise of stock
options.

Sur
December 21, 2018, Company received a conversion notice from a lender. As a result, 9,372,100 shares of CANB common stock was
issued to the lender in satisfaction of notes payable of $83,500 and accrued interest payable of $10,221.

Sur
December 21, 2018, Company issued aggregately 4,370,629 shares of CANB common stock to four officers of the Company in satisfaction
of accrued compensation of $192,300.

Sur
December 28, 2018, the Company issued 3,096,827 shares of CANB common stock for the acquisition of Pure Health Products, LLC.

Sur
December 28, 2018, the Company issued 245,789 shares of CANB common stock to an officer of the Company pursuant to the Employment
Agreement dated December 29, 2018 with Andrew Holtmeyer. The $10,371 fair value of the issuance was charged to stock-based compensation
in the three months ended December 31, 2018.

Sur
December 29, the Company issued 30,000,000 shares of CANB common stock to Marco Alfonsi in exchange for the return of 3 shares
of CANB Series A Preferred Stock owned by Marco Alfonsi.

REMARQUE
12 – Stock Options and Warrants

UNE
summary of stock options and warrants activity follows:

Shares of Common Stock Exercisable Into 

    
    Stock
    
    

    
    Options  
    Mandats
    Total

    Balance, December 31, 2016 
     50,000  
     247,500  
     297,500 

    Granted in 2017 
    –
    –
    –

    Expired in 2017 
    –
    –
    –

    Balance, December 31, 2017 
     50,000  
     247,500  
     297,500 

    Granted in 2018 
     6,000,000  
     2,850,000  
     8,850,000 

    Cancelled in 2018 
    –
    –
    –

    Exercised in 2018 
    –
     (850,000) 
     (850,000)

    Balance, December 31, 2018 
     6,050,000  
     2,247,500  
     8,297,500

Issued
and outstanding stock options as of December 31, 2018 consist of:

Year 
    Number Outstanding
Et
    Exercice
    Year of 

    Granted 
     Exercisable  
    Prix
    Expiration 

    2009
     50,000  
    $1.000  
    2019

    2018
     6,000,000  
    $0.001  
    2023

    Total
     6,050,000

Sur
June 11, 2018, the Company granted 3,000,000 options of CANB common stock to Carl Dilley, a director of the Company, in exchange
for the retirement of a total of 3,000,000 shares of CANB common stock from Carl Dilley. The options are exercisable for the purchase
of one share of the Registrant’s Common Stock at an exercise price of $0.001 per share. The Options are fully vested and
are exercisable as of the Grant Date and all shall expire June 11, 2023. The value of the Stock Options ($84,000) were calculated
using the Black Scholes option pricing model and the following assumptions: (i) $0.028 share price, (ii) 5 years term, (iii) 262.00%
expected volatility, (iv) 2.80% risk free interest rate and the difference between this value and the fair value of retired shares
was expensed in the quarterly period ended June 30, 2018.

Sur
October 21, 2018, the Company granted 3,000,000 options of CANB common stock to Stanley L. Teeple, an officer and Director of
the Company. The options are exercisable for the purchase of one share of the Registrant’s Common Stock at an exercise price
of $0.001 per share. The Options are fully vested and are exercisable as of the Grant Date and all shall expire October 1, 2023.
The values of the Stock Options ($118,200) were calculated using the Black Scholes option pricing model and the following assumptions:
(i) $0.0395 share price, (ii) 5 years term, (iii) 221.96% expected volatility, (iv) 3.05% risk free interest rate and the fair
value of options was expensed in the quarterly period ended December 31, 2018

Issued
and outstanding warrants as of December 31, 2018 consist of:

Year 
    Number Outstanding
Et
    Exercice
    Year of 

    Granted 
     Exercisable  
    Prix
    Expiration 

    2010
     247,500  
    1,00 USD
    2020

    2018
     2,000,000  
    $0.04345(a) 
    2023

    Total
     2,247,500

(une)
110% of the closing price of the Company’s common stock on the date that the Holder funds the full purchase price of the
Note.

REMARQUE
13 – Income Taxes

Non
provisions for income taxes were recorded for the periods presented since the Company incurred net losses in those periods.

le
provisions for (benefits from) income taxes differ from the amounts determined by applying the U.S. Federal income tax rate of
21% and 35% to pretax income (loss) as follows:

Year Ended December 31, 

    
    2018
    2017

    Expected income tax (benefit) at 21% and 35% 
    $(663,578) 
    $(748,902)

    Loss on forgiveness of receivable from Pure Health products 
     18,024  
    

    Loss on stock issuance 
     36,344  
     67,043 

    Loss on debt conversion 
     272,867  
     11,334 

    Non-deductible stock-based compensation 
     583,653  
     81,057 

    Non-deductible amortization of debt discounts 
     37,064  
     87,566 

    Non-deductible impairment of intangible assets 
    –
     7,527 

    Non-deductible expense from derivative liability 
     (334,139) 
     320,495 

    Increase in deferred income tax assets valuation allowance 
     250,235  
     173,879 

    Provision for (benefit from) income taxes 
    $-  
    $-

Deferred
income tax assets consist of:

Le 31 décembre,
    Le 31 décembre,

    
    2018
    2017

    Net operating loss carryforward 
     1,644,593  
     1,394,358 

    Valuation allowance 
     (1,644,593) 
     (1,394,358)

    Net 
    $-  
    $-

Based
on management’s present assessment, the Company has not yet determined it to be more likely than not that a deferred income
tax asset of $1,644,593 attributable to the future utilization of the $4,786,934 net operating loss carryforward as of December
31, 2018 will be realized. Accordingly, the Company has maintained a 100% allowance against the deferred income tax asset in the
financial statements at December 31, 2018. The Company will continue to review this valuation allowance and make adjustments as
appropriate. The net operating loss carryforward expires in years 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034,
2035, 2036, 2037 and 2038 in the amount of $1,369, $518,390, $594,905, $686,775, $159,141, $151,874, $135,096, $166,911, $311,890,
$25,511, $338,345, $386,297, $496,798 and $713,162, respectively.

Actuel
tax laws limit the amount of loss available to be offset against future taxable income when a substantial change in ownership
occurs. Therefore, the amount available to offset future taxable income may be limited.

le
Company’s U.S. Federal and state income tax returns prior to 2014 are closed and management continually evaluates expiring
statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative rulings. The statute of limitations
on the 2014 tax year returns expired in September 2018.

le
Company recognizes interest and penalties associated with uncertain tax positions as part of the income tax provision and would
include accrued interest and penalties with the related tax liability in the consolidated balance sheets. There were no interest
or penalties paid during 2018 and 2017.

REMARQUE
14 – Commitments and Contingencies

Employment
Agreements

Sur
October 3, 2017, the Company executed an Executive Employment Agreement with Marco Alfonsi (“Alfonsi”) for Alfonsi
to serve as the Company’s chief executive officer and interim chief financial officer and secretary for cash compensation
of $10,000 per month. Pursuant to the agreement, the Company issued a share of CANB Series A Preferred Stock to Alfonsi on October
4, 2017 (see Note 8). Alfonsi may terminate his employment upon 30 days written notice to the Company. The Company may terminate
Alfonsi’s employment upon written notice to Alfonsi by a vote of the Board of Directors. At November 12, 2018, this Agreement
was terminated due to the execution of a new Employment Agreement with Marco Alfonsi for Alfonsi to serve as the Company’s
chief executive officer for cash compensation of $15,000 per month. Pursuant to the agreement, three of the eight previously issued
shares of CANB Series A Preferred Stock will be returned to the Company and converted into 30,000,000 common shares. On December
Alfonsi may terminate his employment upon 30 days written notice to the Company. The Agreement has an initial term of four years
and can be terminated upon the resignation or death of Mr. Alfonsi, and also can be terminated by the Company due to the failure
or neglect of Mr. Alfonsi to perform his duties, or due to the misconduct of Mr. Alfonsi in connection with the performance.

Sur
February 12, 2018, the Company executed an Executive Service Agreement (“Agreement”) with David Posel. The Agreement
provides that Mr. Posel services as the Company’s Chief Operating Officer for a term of 4 years. The Agreement also provides
for compensation to Mr. Posel of $5,000 cash per month and the issuance of 1 share of Series A Preferred Stock at the inception
of the Agreement. The Agreement can be terminated upon the resignation or death of Mr. Posel, and also can be terminated by the
Company due to the failure or neglect of Mr. Posel to perform his duties, or due to the misconduct of Mr. Posel in connection
with the performance. On February 12, 2018, 1 share of CANB Series A Preferred Stock were issued to Mr. Posel (see Note 8).

Sur
February 16, 2018, the Company executed an Executive Service Agreement (“Agreement”) with Andrew W Holtmeyer. le
Agreement provides that Mr. Holtmeyer services as the Company’s Executive Vice President Business for a term of 3 years.
The Agreement also provides for compensation to Mr. Holtmeyer of $10,000 cash per month and the issuance of 3, 2 and 1 share of
Series A Preferred Stock at the beginning of each year. The Agreement can be terminated upon the resignation or death of Mr. Holtmeyer,
and also can be terminated by the Company due to the failure or neglect of Mr. Holtmeyer to perform his duties, or due to the
misconduct of Mr. Holtmeyer in connection with the performance. At December 29, 2018, this Agreement was terminated due to the
execution of a new Employment Agreement with Andrew W Holtmeyer. The Agreement provides that Mr. Holtmeyer services as the Company’s
Executive Vice President Business for a term of 4 years. The Agreement also provides for compensation to Mr. Holtmeyer of $15,000
cash per month and the issuance of 245,789 shares of common stock upon signing of the agreement.

Sur
October 15, 2018, the Company executed an Employment Agreement (“Agreement”) with Stanley L. Teeple. The Agreement
provides that Mr. Teeple services as the Company’s Chief Financial Officer and Secretary for a term of 4 years. The Agreement
also provides for compensation to Mr. Teeple of $15,000 cash per month and the issuance of 1 share of Series A Preferred Stock
upon execution of the Agreement. The Agreement can be terminated upon the resignation or death of Mr. Teeple, and also can be
terminated by the Company due to the failure or neglect of Mr. Teeple to perform his duties, or due to the misconduct of Mr. Teeple
in connection with the performance.

Sur
December 28, 2018, the Company executed an Employment Agreement (“Agreement”) with Pasquale Ferro for Mr. Ferro to
serve as Pure Health Products’ president for cash compensation of $15,000 per month and the total issuance of 5 share of
Series A Preferred Stock proportionately vesting at the beginning of each year for a term of 4 years. Mr. Ferro may terminate
his employment upon 30 days written notice to the Company. The Agreement has an initial term of four years and can be terminated
upon the resignation or death of Mr. Ferro, and also can be terminated by the Company due to the failure or neglect of Mr. Ferro
to perform his duties, or due to the misconduct of Mr. Ferro in connection with the performance.

Consulting
Agreements

Sur
July 29, 2017, the Company executed a Consulting Agreement with Andrew W Holtmeyer for Mr. Holtmeyer to serve as the Company’s
consultant for monthly cash payment of $5,000 through July 29, 2018. Effective February 16, 2018, the Company terminated the agreement
due to the replacement of an Executive Service Agreement.

Sur
September 6, 2017, the Company executed a Consulting Agreement with T8 Partners LLC (“T8”) for T8 to serve as
the Company’s consultant for stock compensation of a total of 10,000,000 restricted shares. Pursuant to the agreement,
the Company issued 2,500,000 restricted shares of CANB common stock to T8 on September 7, 2017. Effective October 27, 2017,
the Company terminated the agreement due to non-performance by T8. On July 12, 2018, the Company received a response from T8
Partners LLC (“T8”) confirming that the 2,500,000 shares requested to be returned by the Company in an
arbitration filed on May 11, 2018 will be returned to the Company. The Company is awaiting the result of that
arbitration.

Sur
November 9, 2017, the Company executed a Consulting Agreement with Healthcare Advisory Group Company (“Healthcare”)
for Healthcare to serve as the Company’s consultant for stock compensation of a total of 5,000,000 restricted shares. Pursuant
to the agreement, the Company issued 2,500,000 restricted shares of CANB common stock to Healthcare on November 9, 2017. Effective
March 6, 2018, the Company terminated the agreement due to non-performance by Healthcare.

Bail
Agreements

Sur
December 1, 2014, Prosperity entered into a lease agreement with KLAM, Inc. for office space in Hicksville, New York for an initial
term of one year commencing December 1, 2014. The lease provides for monthly rentals of $2,500 and provides Prosperity an option
to renew the lease after the initial term. The Company has continued to occupy this space after November 30, 2015 under a month
to month arrangement at $2,500 per month. KLAM, Inc. is controlled by the wife of the Company’s chief executive officer
Marco Alfonsi.

Sur
September 11, 2015, the Company executed a lease agreement with an unrelated third party for office space in Hicksville, New York
for a term of 37 months. The lease provides for monthly rentals of $2,922 for lease year 1, $3,009 for lease year 2, and $3,100
for lease year 3. The lease also provides for additional rent based on increases in base year operating expenses and real estate
les taxes. On August 6, 2018, the Company renewed the lease agreement for a term of 36 months starting November 1, 2018. The lease
provides for monthly rentals of $3,193 for lease year 1, $3,289 for lease year 2, and $3,388 for lease year 3.

Location
expense for the year ended December 31, 2018 and 2017 was $67,165 and $65,060, respectively.

À
December 31, 2018, the future minimum lease payments under non-cancellable operating leases were:

Year ended December 31, 2019 
     38,508 

    Year ended December 31, 2020 
     39,666 

    Year ended December 31, 2021 
     33,880 

    Total
    $112,054

Major
Les clients

Pour
the year ended December 31, 2018, one customer accounted for approximately 16% of total revenues.

Pour
the year ended December 31, 2017, three customers accounted for approximately 45%, 29% and 14%, respectively, of total service
revenues.

Public
Offering of Units

Sur
August 2, 2016, the Company’s Registration Statement on Form S-1 was declared effective by the Securities and Exchange Commission.
On a self-underwritten basis, the Company was offering up to 40,000,000 Units at a price of $0.05 per Unit or $2,000,000 maximum.
Each Unit consisted of one share of Company common stock and one warrant to purchase ½ share of Company common stock at
a price of $0.10 per share for a period of three years. There was no minimum offering amount or escrow required as a condition
to closing. The offering terminated May 17, 2017.

REMARQUE
15 – Related Party Transactions

ProAdvanced
Group, Inc. (“PAG”), an entity controlled by the Company’s chief executive officer, is a customer of CANB. À
December 31, 2018, CANB had an account receivable from PAG of $7,240. For the year ended December 31, 2018, CANB had revenues
from PAG of $5,000.

Île
Stock Transfer (“IST”), an entity controlled by Carl Dilley, a former Company director, is both a customer and vendor
of CANB. At December 31, 2018, CANB had an account receivable from IST of $7,035 and an account payable to IST of $1,454. Pour
the year ended December 31, 2018, CANB had revenues from IST of $4,000.

Stock
Market Manager, Inc. is also an entity controlled by Mr. Dilley. For the year ended December 31, 2018, CANB had an account payable
to Stock Market Manager Inc. of $1,676.

Dans
order to facilitate its operations, the Company has entered into a Production Agreement with Pure Health Products, LLC (“PHP”),
a New York limited liability company. Pursuant to the Production Agreement, PHP will manufacture, package, and sell the Company’s
CBD infused products on an exclusive basis. PHP will not produce or manufacture any product containing any cannabis or hemp derivative
for any person or entity other than the Company, and the Company controls the ingredients, recipe, manufacturing processes and
procedures and quality and taste parameters for all Products produced at the PHP facility. PHP may also white label / rebrand
or relabel the products on the Company’s behalf pursuant to “white label agreements” entered into between the
Company and third-party customers. Credit card sales are processed through PHP as well. Through its contractual relationship with
PHP, the Company is able to control the manufacturing process of its products while reducing its production costs. En outre,
the Company has the option to acquire certain assets of PHP should it elect to take over direct manufacture of its Products. Pour
the year ended December 31, 2018, purchase of CBD infused products from PHP totaled $274,556.50. Effective December 28, 2018,
the Company acquired Pure Health Products, LLC.

During
the year ended December 31, 2018, we had products and service sales to related parties totaling $5,000.

REMARQUE
16 – Subsequent Events

Sur
January 28, 2019, the Company issued 10,000,000 shares of CANB common stock to a consultant of the Company in exchange for the
retirement of 1 share of CANB Series A Preferred Stock.

De
February 21, 2019 to March 12, 2019, the Company issued aggregately 20,221,436 shares of CANB common stock to RedDiamond in exchange
for the retirement of 157,105 shares of CANB Series B Preferred Stock.

De
January 4, 2019 to March 27, 2019, the Company issued aggregately 41,431,994 shares of CANB common stock to multiple investors
pursuant to relative Stock Purchase Agreements dated on various dates, in exchange for total proceeds of $1,196,100.

Sur
January 14, 2019, the Company and PHP (collectively, the “buyer”) entered into a License and Acquisition Agreement
(the “LAA”) with Hudilab, Inc. (“HUDI”). Pursuant to the LAA, HUDI will sell the technology owned by it
to the buyer in exchange for 7,500,000 shares of CANB common stock. On January 14, 2019, the shares were issued to the owner of
HUDI.

De
January 18, 2019 to March 17, 2019, the Company issued aggregately 24,600,000 shares of CANB common stock to multiple consultants
for services rendered.

De
January 19, 2019 to March 27, 2019, the Company issued aggregately 1,167,959 shares of CANB common stock to employee and officers
of the Company pursuant to employee agreement and in satisfaction of accrued compensation for the quarter ended March 31, 2019.

Sur
January 31, 2019, PHP entered into an Asset Purchase Agreement (the “Agreement”) with Seven Chakras, LLC (“Seven
Chakras”). Pursuant to the Agreement, PHP purchased the rights and title to (i) Seven Chakras’ proprietary formulas,
methods, trade secrets, and know-how related to the production of Seven Chakras’ products containing cannabidiol (“CBD”),
(ii) Seven Chakras’ tradename, domain name, and social media sites, and (iii) other assets of Seven Chakras including but
not limited to raw materials, equipment, packaging and labeling materials, mailing lists, and marketing materials (collectively,
the “Assets”). On February 20, 2019, the Company issued 1,000,000 shares of CANB common stock to owners of Seven Chakras
pursuant to the agreement.

Sur
February 5, 2019, the Company issued 2,000,000 shares to the owner of TZ Wholesale LLC, pursuant to a Memorandum of Understanding
(the “MOU”) dated November 9, 2018.

Comme
a result of Canbiola’s acquisition of Pure Health products, it conducted a corporate re-alignment including naming Pasquale
Ferro President and moving David Possel from Chief Operating Officer of Canbiola to Chief Operations Officer Pure Health Products.

Dans
accordance with FASB ASC 855, Subsequent Events, the Company has evaluated subsequent events through October 30, 2018, the date
on which these consolidated financial statements were available to be issued. Except as disclosed above, there were no material
subsequent events that required recognition or additional disclosure in these consolidated financial statements.

Exhibit
31.1

CERTIFICATION
OF CHIEF EXECUTIVE OFFICER

PURSUANT
TO SECTION 302 OF THE

SARBANES-OXLEY
ACT OF 2002

I,
Marco Alfonsi, certify that:

1.
I have reviewed this Annual Report on Form 10-K/A of Canbiola, Inc.

2
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
to the period covered by this report;

3
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;

4
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(une)
    conçu
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to
    us by others within those entities, particularly during the period in which this report is being prepared;

    
    (b)
    conçu
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
    our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
    statements for external purposes in accordance with generally accepted accounting principles;

    
    (c)
    évalué
    the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions
    about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based
    on such evaluation; et

    
    (ré)
    divulguée
    in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s
    most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially
    affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;
    et

5
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors
(or persons performing the equivalent functions):

(une)
    tout
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
    are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial
    information; et

    
    (b)
    tout
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s
    internal control over financial reporting.

Dated:
    17 avril 2019
    Par:
    /s/
    Marco Alfonsi

    
    
    Marco
    Alfonsi

Chef
                                         Executive Officer

(Principal
        Executive Officer)

Exhibit
31.2

CERTIFICATION
OF CHIEF FINANCIAL OFFICER

PURSUANT
TO SECTION 302 OF THE

SARBANES-OXLEY
ACT OF 2002

I,
Stanley L. Teeple, certify that:

1.
I have reviewed this Annual Report on Form 10-K/A of Canbiola, Inc.

2
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
to the period covered by this report;

3
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;

4
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(une)
    conçu
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to
    us by others within those entities, particularly during the period in which this report is being prepared;

    
    (b)
    conçu
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
    our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
    statements for external purposes in accordance with generally accepted accounting principles;

    
    (c)
    évalué
    the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions
    about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based
    on such evaluation; et

    
    (ré)
    divulguée
    in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s
    most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially
    affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;
    et

5
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors
(or persons performing the equivalent functions):

(une)
    tout
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
    are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial
    information; et

    
    (b)
    tout
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s
    internal control over financial reporting.

Dated:
    17 avril 2019
    Par:
    /s/
    Stanley L. Teeple

    
    
    Stanley
    L. Teeple

Chef
                                         Financial Officer

(Principal
        Financial Officer)

Exhibit
32.1

CERTIFICATION
OF CHIEF EXECUTIVE OFFICER

PURSUANT
TO 18 U.S.C. SECTION 1350

COMME
ADOPTED PURSUANT TO

SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002

Dans
connection with the Annual Report of Canbiola, Inc. (the “Company”) on Form 10-K/A for the period ended December 31,
2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Marco Alfonsi, Chief
Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that:

(1)
    le
    Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended;
    et

    
    (2)
    le
    information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
    de la compagnie.

Rendez-vous amoureux:
    17 avril 2019
    Par:
    /s/
    Marco Alfonsi

    
    
    Marco
    Alfonsi

    
    
    Chef
    Executive Officer

UNE
signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise
adopting the signature that appears in typed form within the electronic version of this written statement has been provided to
the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

Exhibit
32.2

CERTIFICATION
OF CHIEF FINANCIAL OFFICER

PURSUANT
TO 18 U.S.C. SECTION 1350

COMME
ADOPTED PURSUANT TO

SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002

Dans
connection with the Annual Report of Canbiola, Inc. (the “Company”) on Form 10-K/A for the period ended December 31,
2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Stanley L. Teeple,
Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that:

(1)
    le
    Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended;
    et

    
    (2)
    le
    information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
    de la compagnie.

Rendez-vous amoureux:
    17 avril 2019
    Par:
    /s/
    Stanley L. Teeple

    
    
    Stanley
    L. Teeple

    
    
    Chef
    Financial Officer

UNE
signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise
adopting the signature that appears in typed form within the electronic version of this written statement has been provided to
the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.